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ORGANOCATALYTIC, MICHAEL-STETTER REACTION AND  
RHODIUM(I)-CATALYZED HYDROHETEROARYLATION OF ACRYLATES WITH BENZOXAZOLES: 




The chapters that follow describe two independent investigations. Both relay the development of experimental 
methods for the catalytic, asymmetric addition of carbon–hydrogen bonds to alkenes. In the first chapter, 
nucleophilic amine and N-heterocyclic carbene cocatalysts cooperate in the organocatalytic, cascade synthesis of 
benzofuranone products in good yields and high enantioselectivities. Importantly, the cascade protocol is found to 
outperform a two-pot procedure in which reaction intermediates are isolated and purified before the second step. 
Mechanistic studies reveal that additives and geometry of an olefin intermediate crucially influence reaction 
enantioselectivity. In the second method, a bulky Rh(I)–bisphosphine complex catalyzes the asymmetric, 
intermolecular addition of benzoxazoles to methacrylate derivatives in fair to excellent yields and good to excellent 
enantioselectivities. Detailed deuterium labeling and epimerization studies provide considerable insight into the 
reaction mechanism: C–H activation is reversible; migratory insertion is likely enantiodetermining; and the bulky-
bisphosphine ligand likely boosts reactivity and selectivity by discouraging deleterious ligation of benzoxazole 
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At 1.4 million atmospheres 
xenon, a gas, goes metallic. 
Between squeezed single-bevel 
diamond anvils jagged bits 
of graphite shot with a YAG 
laser form spherules. No one 
has seen liquid carbon. Try 
to imagine that dense world 
between ungiving diamonds 
as the pressure mounts, and 
the latticework of a salt 
gives, nucleating at defects 
a shift to a tighter order. 
Try to see graphite boil. Try 
to imagine a hand, in a press, 
in a cellar in Buenos Aires, 
a low-tech press, easily 
turned with one hand, easily 
cracking a finger in another 
man's hand, the jagged bone 
coming through, to be crushed 
again. No. Go back, up, up 
like the deep diver with 
a severed line, up, quickly, 
 viii 
to the orderly world of ruby 
and hydrogen at 2.5 megabar, 
the hydrogen coloring near 
metallization, but you hear 
the scream in the cellar, don't 
you, and the diver rises too fast. 
 
 













Cascade catalysis has garnered significant recent attention from the synthetic community as a means to swiftly 
assemble complex molecules from simple starting materials with minimal time, waste and manipulation of reaction 
intermediates.[2] Especially powerful in its application to total synthesis, asymmetric tandem catalysis has enabled 
rapid access to enantioenriched products with high levels of selectivity.[2b,2d–h,2i,2k] Although most examples exploit a 
single catalyst to promote multiple, sequential transformations,[3] systems relying on two or more catalysts have 
been reported.[2a,2c,2k,4] Inherent in any multiple catalyst system is the challenge of compatibility. Avoidance of 
mutual interference often obliges step-wise addition of catalysts or reagents and variation of reaction conditions over 
time.[5] Nevertheless, cascades triggered by a single operation have been accomplished.[4,6]  
In 2012, we reported the development of a one-step, asymmetric Michael–benzoin reaction of β-ketoesters 1 
and α,β-unsaturated aldehydes 2 mediated by compatible amine 3 and N-heterocyclic carbene (NHC, conjugate base 
of 4a) catalysts (Figure 1.1).[7] Importantly, the one-pot procedure was found to give elaborated cyclopentanone 
products 5 in higher yield and enantioselectivity than a step-wise protocol, wherein intermediate aldehyde 6 is 
isolated and subjected to the benzoin reaction in a subsequent step (Figure 1.1). This observation testifies to the 
power of cascade catalysis: by quickly relaying intermediates from one reaction to the next, catalysts can work 
synergistically to discourage undesired pathways. 
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Encouraged by the discovery that NHCs could participate in cascade catalysis, we were inspired to use NHCs to 
mediate the cascade assembly of benzofuranone products 9 asymmetrically.[8] A range of biological activities 
associated with 3(2H)-benzofuranones including antifungal,[9] anti-psychotic[10] and anti-cancer[11] properties make 
these products attractive synthetic targets. Among recently-synthesized natural products 
containing a 2,2’-disubstituted benzofuranone core, rocaglamide demonstrates appreciable 
cytotoxicity in mice and human cells lines,[12] vinigrol displays anti-hypertensive properties[13] and 
Sch202596 shows promise in Alzheimers therapy.[14] 
Although a number of methods for the racemic assembly of benzofuranones containing C2 quaternary centers 
have been reported, many proceed from relatively advanced starting materials[15] or suffer from competitive reaction 
pathways.[16] More rare are enantioselective preparations of 2,2’-disubstituted benzofuranones. In 2008, Jørgensen 
and coworkers reported that 2-tert-butyloxy carbonyl benzofuranone could be alkylated asymmetrically with 
tetraethyl ethylidene-bisphosphonate to give the corresponding 2,2’-disubstituted product in excellent 
enantioselectivity.[17] In a different approach, we have shown that chiral triazolinylidene carbenes mediate the 
cyclization of aldehyde-tethered, β,β-disubstituted Michael acceptors related to 12 to give benzofuranone products 
in excellent enantioselectivities (Figure 1.2, 12 ! 9).[18]  
Figure 1.2 Envisioned multicatalytic Michael–Stetter cascade 
Although the strategies described provide benzofuranone products in good yield and exceptional selectivities, 
both make use of substrates that require multiple steps to prepare.[18b] We imagined that we could expedite the 
synthesis of benzofuranone products 9 by assembling intermediate aldehydes 12 in situ via a base-catalyzed 

















































coworkers have shown that 1,4-diazabicyclo[2.2.2]octane (DABCO) (10) efficiently mediates the addition of amine 
and oxygen nucleophiles to dimethyl acetylenedicarboxylate (DMAD) (8a) and alkyl propiolates.[19]  In our 
envisioned sequence, a tertiary amine such as quinuclidine (11) or DABCO (10) activates alkyne 8 toward 
nucleophilic attack to give intermediate aldehyde 12 (Figure 1.2, 7 ! 12). Subsequent chiral carbene-promoted 
Stetter reaction sets a quaternary stereocenter and yields product 9 asymmetrically (Figure 1.2, 12 ! 9). 
Crucial to the success of any catalytic cascade is a compatible catalyst system. For many Stetter systems, 
tertiary amines perform as optimal bases for carbene generation.[18b,20] For this reason, we were encouraged that 
DABCO or quinuclidine would not only serve as nucleophilic “triggers”[19a] to promote our imagined conjugate 
addition reaction but would also prove suitable bases to deprotonate triazolium salt precatalyst 4b and generate the 
active carbene species.  
1.2 Results and discussion 
1.2.1 Reaction optimization and salicylaldehyde scope 
We first examined whether our envisioned cascade could be performed in a one-pot, step-wise fashion. 
Carbenes have been shown capable of nucleophilic addition into DMAD and other activated alkynes.[21] To 
circumvent this undesired reaction pathway, a mixture of salicylaldehyde (7a) and DMAD (8a) was treated first with 
quinuclidine 11 and then with triazolium salt 4b in a second step. Benzofuranone product 9aa was isolated from this  
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one-pot, two-step sequence in good overall yield and enantioselectivity (Table 1.1, entry 1). In a brief solvent screen, 
dichloromethane (DCM) and 9:1 toluene/t-amyl alcohol (PhMe/TAA) provided product 9aa in similarly high yields 
(Table 1.1, entries 1 and 4), while toluene gave the highest level of enantioselectivity (Table 1.1, entries 1–5). 
Lowering temperatures of the Stetter reaction (step 2) improves enantioselectivity slightly but results in longer 
reaction times and lower product yields (Table 1.1, entries 6–8). No productive reaction is observed when the 
conjugate addition reaction is conducted at low temperature (Table 1.1, entry 9). 
Although we had developed conditions to mediate two bond-forming events in one reaction vessel with high 
levels of asymmetric induction, we hoped to reduce the number of required synthetic manipulations to a single 
operation. To this end, we treated a mixture of 7a, 8a and 4b with quinuclidine (11) at 0 °C in toluene. To our 
delight, the cascade proceeds smoothly to give 9aa in undiminished yield and enantioselectivity (eq. 1). The one-
step protocol was found to be scalable: on a 1 g scale, product 9aa (1.48 g, 79% yield) is obtained in 88% ee. When 
the one-step reaction is performed in dichloromethane, however, only starting material and decomposition products 
are recovered; under these conditions, nucleophilic addition of 4b-derived carbene into DMAD21 may interfere with 
the desired conjugate addition reaction (eq. 1). 
A series of control experiments were performed to probe the mechanism of the conjugate addition reaction. We 
had envisioned that Michael addition proceeds through nucleophilic activation of DMAD via intermediate I (Figure 
1.2). However, an alternative pathway could be imagined in which quinuclidine deprotonates salicylaldehyde, which 
adds conjugately to DMAD. To examine the viability of a base-catalyzed pathway, we exchanged quinuclidine for 
diisopropylethylamine (DIPEA)— DIPEA should have similar basicity to quinuclidine (11), but since it is much 
bulkier than 11, it should be much less nucleophilic. Treatment of salicylaldehyde and DMAD with this less 
competent nucleophile but similarly strong base resulted in complete recovery of starting material (eq. 2), suggesting 
that the proposed nucleophilic pathway is indeed at work in our developed conditions. Moreover, exposure of 
salicylaldehyde and DMAD to the free carbene derived from azolium salt 4b gave no discernable product by 1H 
NMR spectroscopy (eq. 3). Thus, it is highly probable that quinuclidine (11) rather than carbene-4b participates as 
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With a productive one-step protocol in hand, we investigated the scope of the reaction with respect to 
salicylaldehyde 7. Indeed, both electron-rich and electron-deficient salicylaldehydes with various substitution 
patterns participate in the Michael–Stetter sequence to give products 9 in good yields and moderate to excellent 
enantioselectivites (Table 1.2). Electron-deficient salicylaldehydes give generally higher enantioselectivities but 
poorer yields than electron-rich salicylaldehydes.  The lower yields observed for these substrates are attributed to 
competitive formation of chromene side-products 13 derived from intramolecular aldol of intermediate enolate III 
(eq. 4, vide infra, section 1.2.4). 3-Substituted salicylaldehydes give the lowest observed yields; steric bulk 
surrounding the phenoxide likely impedes nucleophilic addition into DMAD (Table 1.2, 9ia–9ja). Indeed, when the 
3-substituent is sufficiently large, no conjugate addition is observed (Table 1.2, 9ja). Absolute configuration of 
products 9 was assigned by X-ray crystal structure of iodide 9da. The others were assigned by analogy. 
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< 5%, ee ND
base = 11
 6 
1.2.2 Investigations into reaction enantioselectivity 
We were intrigued by the variation of enantioselectivity across products 9 which appeared to be independent of 
steric or electronic factors. For example, 4- and 5-methoxy substrates 7h and 7g provide products with identical ees 
in spite of their differing electronic impact on both aldehyde and tethered alkene (Table 1.2, 9ga vs. 9ha).  
Furthermore, sterically similar substrates 7d and 7e give products with disparate ees (Table 1.2, 9da vs. 9ea, 94 and 
86% ee respectively, corresponding to ~0.5 kcal/mol energy difference).   
To probe the origin of ee variation, we performed a two-pot Michael–Stetter protocol wherein intermediate 
aldehyde 12 was isolated, purified and subjected to Stetter conditions in a second step (Table 1.3). Treatment of 
DMAD and salicylaldehydes 7f, 7a, and 7c with base gives the corresponding intermediate aldehydes 12fa, 12aa, 
and 12ca in good yields (Table 1.3). When intermediate aldehydes 12fa, 12aa, and 12ca are exposed to precatalyst 
4b and base in the usual manner, however, products 9fa, 9aa, and 9ca are obtained in appreciably lower and more 
uniform enantioselectivities than those observed in the one-pot procedure (Table 1.3).  
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82% ee 85% ee
87% 78%
84% ee 89% ee
86% 64%





Two-pot: 12 is isolated and purified prior to 2nd step. 
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We speculated that a trace impurity present in or side-product derived from certain salicylaldehydes 7 might be 
crucial for the high enantioselectivities obtained in the one-pot protocol; removal of the species during isolation of 
intermediate 12 could result in a drop in enantioselectivity of the subsequent Stetter reaction. Indeed, when Stetter 
reactions of intermediate aldehydes 12ca and 12fa are conducted in the presence of an equivalent of exogenous 
salicylaldehyde 7c (which gives product 9ca in high ee in the one-pot protocol), the high enantioselectivities of 
products 9ca and 9fa are recovered (Table 1.4, entries 1 and 3). 
Table 1.4 Additive effect on Stetter enantioselectivity 
We aimed to identify the species present in exogenous salicylaldehydes 7 that might promote elevation of 
enantioselectivity. Strong H-bond donors such as catechols have been shown to improve yields and 
enantioselectivities of enamine-promoted Michael additions of aldehydes into enones.[22] We hypothesized that trace 
catechol derived from Dakin oxidation[23] of the salicylaldehyde might contribute to Stetter enantioselectivity. 
Consistent with this theory, addition of 10 mol % catechol 14a to the Stetter reaction of intermediate aldehydes 12ca 
and 12fa improves product enantioselectivities to excellent 94% ee and 92% ee, respectively (Table 1.4, entries 2 
and 4).  
When catechol 14a is added with precatalyst 4b in the one-pot, two-step protocol, similar improvement in 
enantioselectivity is observed for a variety of substrates (Table 1.5, entries 1–3). On the other hand, addition of 14a 
in the one-pot, one-step procedure provides virtually no change in selectivity (data not shown). Presumably, catechol 
14a adds conjugately to DMAD (8a) in these cases,[19a] and the Stetter reaction proceeds with unimproved 
selectivity, since no free catechol exists in the reaction media at the time of the second step. Finally, an observed 
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the Stetter reaction. When chiral, binapthyl-derived catechol 14b is used as an additive, enantioselectivity of product 
9aa improves from 89% ee to 95% ee with (S,R)-precatalyst 4b but shows no change with (R,S) precatalyst ent-4b 
(Table 1.5, entries 4 and 5). Although the exact mechanism by which catechol improves enantioselectivities of 
products 9 is not fully understood, it appears that the 1,2-difunctionality of catechol rather than its low pKa is 
responsible for ee elevation: when catechol 14a is replaced with acidic phenol 14c, no improvement in 
enantioselectivity of products 9 is observed (Table 1.5, entry 6).[24] 
Table 1.5 Catechol effect on enantioselectivity in the one-pot, two-step Michael–Stetter reaction 
 
1.2.3 Unsymmetrical alkynes and electron-deficient terminal allenes as Michael acceptors 
Having explored the scope and selectivity of our Michael–Stetter reaction between DMAD and a variety of 
salicylaldehydes, we focused on incorporation of unsymmetrical alkynes as Michael acceptors in this cascade. 
Ketoalkynoates 8b and 8c participate in the one-step reaction with salicylaldehyde (7a) to give moderate yields of 
products 9ab and 9ac regioselectively but with low enantioselectivity (Table 1.6). Attenuation of alkyne 
electrophilicity by substitution of the aryl ketone with phenethyl ketone improved the enantioselectivity of major 
product 9ad but resulted in formation of a second regioisomer 15ad in ~10% yield. Interestingly, minor regioisomer 
15ad is obtained in high enantioselectivity relative to major product 9ad (Table 1.6, footnote 2). Finally, 
phosphonate ester 8e reacts in a one-pot, two-step protocol to give 9ae in fair yield and good enantioselectivity 








1) 11 (20 mol %) 
2) 4 (20 mol %)
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Table 1.6 Unsymmetric alkyne scope[1] 
[1]Product ratio determined by 1H NMR of the crude reaction mixture. [2]Minor regioisomer (15ad) isolated in 9% 
yield and 89% ee. [3]9ae was prepared in a one-pot, two-step sequence (see Appendix One). 
Although we were pleased to find that a number of unsymmetrical alkynes were tolerated in our one-pot 
protocol, we were interested in identifying substrates that would participate with high levels of both regioselectivity 
and enantioselectivity. Intermediate aldehydes 16 containing a single electron-withdrawing substituent on the 
Michael acceptor have been shown to undergo the Stetter reaction with high enantioselectivity under conditions 
similar to these (eq. 5).[18b] Our initial attempt to access related intermediate aldehyde 16 via the necessarily 
regioselective Michael addition of salicylaldehyde (7a) into singly activated alkynoate 17 resulted only in isolation 
of starting material and decomposition products (eq. 6).[25] Nevertheless, we were encouraged to try other modes of 
entry to intermediates 16. Shi and coworkers have shown that activated allenes behave as alkyne surrogates in a 
DABCO-catalyzed conjugate addition reaction with salicylaldehyde.[25] Indeed, we were delighted to find that 
subjection of allenone 18a and allenoate 18b to our one-pot, two-step protocol in a variety of solvents gave 
























































































11 (20 mol %)
 10 
Table 1.7 One-pot, two-step Michael–Stetter reaction with activated allenes 
We hoped to understand why certain substrates (DMAD, allenoate 18b) react with much greater 
enantioselectivity than others (ketoalkynoates 8b and 8c). A factor that has been shown to influence Stetter 
enantioselectivity is olefin geometry.[18a–b] While intermediate aldehydes 12aa and 16b (derived from DMAD and 
allenoate 18b, respectively) form with near perfect E-selectivity under our conditions (eq. 7), intermediate aldehydes  
derived from ketoalkynoate substrates (8b–d) are observed as unselective mixtures of E and Z isomers (eq. 8).  
For a number of Stetter scaffolds, the E-isomer has been shown to react in higher yield and with greater 
enantioselectivity than the corresponding Z-isomer.[18a–b] To examine whether a relatively high Z to E ratio could 
contribute to the low enantioselectivities obtained for ketoalkynoate substrates 8a–c, we subjected a 6.5:1 Z to E 
mixture[26] of intermediate aldehyde 12aa to our established Stetter conditions. Whereas E-12aa reacts to afford 
product 9aa in 84% ee, Z-enriched 12aa gives 9aa in only 29% ee and in appreciably lower yield (eq. 9). The 
disparity in enantioselectivity across batches of intermediate aldehyde 12aa suggests that striking differences in E to 
Z ratios of conjugate adducts 12aa and 16b on one hand, and 12ab–12ad on the other, may contribute significantly 
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1.2.4 Side products and rationale for base selection 
As described in the discussion of salicylaldehyde scope (Table 1.2), we found that electron-deficient 
salicylaldehydes 7 (i.e. 7b–d, 7g and 7i) provided lower yields of product 9 than their electron-rich counterparts (7a, 
7e–f) (62–68% yield vs. 73–80% yield). This yield reduction was attributed to competitive formation of aldol 
adducts 13 from enolate intermediate III (eq. 4, vide supra). An elaboration of this hypothesis is provided below.  
In 1975, Gupta and George reported that salicylaldehyde (7a) and DMAD (8a) react under basic conditions to 
provide a complex product mixture (eq. 10).[26] In addition to the maleate and fumarate adducts 12aa-E and 12aa-Z 
(which are the intermediates exploited in our Michael–Stetter sequence—see, for instance, Figure 1.2 or Table 1.1), 
Gupta and George observe chromenol product 13 and its isomer 20. The mechanism of formation of 13 and 20 
presumably begins as for conjugate adducts 12aa-E and 12aa-Z: addition of the conjugate base of salicylaldehyde 
into DMAD provides allenolate IV (eq. 11). Whereas protonation of IV furnishes 12aa-E and 12aa-Z (path not 
shown), an intramolecular aldol reaction of allenolate IV onto the tethered aldehyde delivers chromenol 13. Some 
13 isomerizes to chromenol 20 on silica gel, presumably via benzopyrilium cation V.  
 If Gupta and George’s mechanism is correct, then product selectivity is controlled by relative rates of two 
competitive processes: reaction of allenolate IV with proton to give conjugate adducts 12aa; or reaction of allenolate 
IV with tethered aldehyde to give aldol adduct 13. We postulate that our mechanism may provide a similar 
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provides enolate intermediate VI, which resembles the allenolate intermediate IV invoked by Gupta and George. In 
our case, formation of products 12 does not proceed via protonation of enolate VI but by expulsion of the tertiary 
amine leaving group (path B, eq. 12). As in Gupta and George’s case, however, enolate VI can undergo competitive 
cyclization, which, after loss of tertiary amine, provides aldol adduct 13 (path A, eq. 13).[27] Notably, this 
mechanism is consistent with our previous observation that electron-deficient salicylaldehydes provide lower yields 
of Stetter product 9 in the one-pot protocol (Table 1.2); the undesired aldol reaction should be more competitive for 
adducts VI derived from electron-poor salicylaldehydes than for electron-rich or electron-neutral aldehydes, since 
electron-poor aldehyde adducts VI are better carbon electrophiles.  
Finally, the invoked aldol pathway helps rationalize an observed yield-dependence on base identity. We found 
that choice of 3o amine catalyst exhibited a subtle but notable influence on reaction yield and purity. Specifically, 
reactions of electron-poor aldehydes 9b–c, 9g and 9i appeared cleaner and slightly higher yielding when DABCO 
(10) was used in the place of quinuclidine (11). This observation is consistent with operation of the competitive 
paths shown in equations 12 and 13. Slightly less basic than quinuclidine, DABCO (pKaH = 8.8 vs. 11)[28] should be 
a better leaving group, and it should consequently be expelled more readily by enolate VI via path B (eq. 12). Use of 
DABCO in the place of more basic quinuclidine, then, mitigates some yield loss experienced in reactions of 
aldehydes 7b–c, 7g and 7i, since it accelerates desired formation of conjugate adduct 12 relative to undesired 
intramolecular aldol addition via path A (eq. 13).  
1.2.5 Substrate limitations 
As discussed in the Chapter (Table 1.7), we found that activated terminal allenes 18 could participate in a one-
pot, two-step Michael–Stetter reaction with salicylaldehydes 7 to provide benzofuranone product 19 in moderate 
yield and good to excellent enantioselectivity (eq. 14). We wondered, in light of this discovery, whether activated, 
internal allenes 21 could perform as competent substrates in the cascade reaction (eq. 15). Use of internal allenes 


























X = halogen, OMe: e- poor
X = H, alkyl: e- rich
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19, substitution at the stereogenic carbon of 19 is limited to methyl (eq. 14). Use of internal allenes, on the other 
hand, would enable decoration of benzofuranone products 22 with diverse alkyl groups (eq. 15). 
We began our investigations by testing just the conjugate addition reaction of salicylaldehyde 7a with racemic 
internal allene ethyl 2,3-pentadienoate (21a) (Figure 1.3a, eq. 16). When quinuclidine (11) is used as the 
nucleophilic catalyst, no conjugate adduct 23aa is obtained even at elevated temperatures. We wondered how ethyl 
2,3-pentadienoate (21a) differed from terminal allenoate 18b (Table 1.7). One hypothesis explains reluctant 
conjugate addition of 21a in terms of allylic 1,3-strain (A[1,3]-strain)  (Figure 1.3b). Because of the presence of the 
alkyl group (CH3) in 21a, development of A[1,3]-strain in intermediates VII or VIII derived from conjugate 
addition of quinuclidine (11) into ethyl 2,3-pentadienoate (21a) is inevitable. If quinuclidine (11) adds cis to the 
methyl group of 21 (path A, Figure 1.3b), the methyl group and 11 will experience allylic strain with each other in 
intermediate VII (Figure 1.3b). In what is presumably the more favorable approach, quinuclidine adds trans to the 
methyl group 21a (path B, Figure 1.3b). This approach forces the methyl group and the enolate to adopt a cis 
relationship in intermediate VIII. While A[1,3]-strain exhibited by VIII is relatively mild, the barrier to formation 
of VIII is still higher than when the methyl group of 21a is absent. 
Figure 1.3 Internal allenes do not participate in the desired nucleophile-promoted conjugate addition reaction 
We sought to overcome presumed high barriers to conjugate addition by increasing catalyst nucleophilicity or 
substrate electrophilicity. Unfortunately, reaction of salicylaldehyde 7a with allenoate 21a to give product 23aa fails 
even in the presence of nucleophilic dimethylphenyl phosphine (PhPMe2) catalyst; and quinuclidine-catalyzed 
reaction of 7a with electrophilic allenone 21b provides a mixture of products that does not include discernable 

















































21a: R = OEt







23aa: R = OEt
23ab: R = Ph
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1.3 Summary 
In summary, we have described a novel and scalable one-pot procedure for the highly enantioselective 
preparation of benzofuranone products from simple starting materials. We have demonstrated that the one-pot 
Michael-Stetter protocol is superior to the two-step procedure with respect to enantioselectivity, and we have 
expanded on this observation to show that catechol additives improve enantioselectivity in the context of both two-
pot and one-pot, two-step reactions. Moreover, we have identified olefin geometry as an important factor 
influencing Stetter enantioselectivity. Finally, we have illustrated that activated allenes behave as competent, E-
selective Michael acceptors in our one-pot, two-step reaction to provide access to alkyl-substituted benzofuranones 
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Asymmetric hydroheteroarylation (HH) of alkenes represents a convenient entry to elaborated heterocyclic 
motifs. While chiral acids are known to mediate asymmetric addition of electron rich heteroarenes to Michael 
acceptors, very few methods exploit transition-metals to catalyze alkylation of heterocycles with olefins via a C–H 
activation, migratory insertion sequence. Herein, we describe the development of an asymmetric, intermolecular 
hydroheteroarylation reaction of α-substituted acrylates with benzoxazoles. The reaction provides 2-substituted 
benzoxazoles in moderate to excellent yields and good to excellent enantioselectivities. Notably, a series of 
mechanistic studies appears to contradict a pathway involving enantioselective protonation of a Rh(I)–enolate, 
despite the fact that such a mechanism is invoked almost unanimously in the related addition of aryl boronic acids to 
methacrylate derivatives. Evidence suggests instead that migratory insertion or β-hydride elimination is 
enantiodetermining and that isomerization of a Rh(I)–enolate to a Rh(I)–heterobenzyl species insulates the resultant 
α-stereocenter from epimerization. A bulky ligand, CTH-(R)-Xylyl-P-Phos is crucial for reactivity and 
enantioselectivity, as it likely discourages undesired ligation of benzoxazole substrates or intermediates to on- or 
off-cycle rhodium complexes and attenuates coordination-promoted product epimerization.  
2.2 Introduction 
Catalytic, enantioselective addition of a C–H bond of a heterocycle across an alkene represents a conceptually 
simple and atom economical method for the preparation of elaborated heterocyclic scaffolds. This concept has been 
implemented in a formal sense in the asymmetric Friedel–Crafts alkylation of electron rich heteroarenes, such as 
indoles, with Michael acceptors.[ 2 ] Yet methods exploiting transition-metals to mediate asymmetric 
hydroheteroarylation of alkenes via a C–H activation, insertion sequence remain quite elusive.[3–4] This deficiency is 
somewhat surprising given the diverse methods for asymmetric hydroarylation of olefins with activated arenes[5] or 
with arenes containing directing groups for C–H functionalization.[6] In the early 2000s, Bergman and Ellman 
pioneered the achiral, intramolecular HH of unactivated alkenes with a Rh(I)–phosphine catalyst.[4a] This discovery 
was expanded in a great body of work to the intermolecular HH reaction of alkenes[7] and to several discrete 
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asymmetric, intramolecular HH reactions.[8 ] In 2012, Shibata provided an early example of an asymmetric 
intermolecular HH reaction mediated by a transition-metal (TM):[9] an Ir(I)–SDP-catalyst promotes the branched-
selective alkylation of N-benzoylindole and styrene in 42% ee (Figure 2.1, eq. 1). Notably, alkylation occurs at the 
indole 2-position, whereas functionalization typically proceeds at the 3-position under Friedel–Crafts conditions.[2] 
Though only modestly selective, Shibata’s example foreshadows that TM-catalyzed HH may eventually serve as a 
selective and general complement to established methods using chiral acids. Indeed, Hartwig and Sevov described in 
short succession the asymmetric HH of norbornene with diverse heterocycles using a chiral Ir(I) catalyst (Figure 2.1, 
eq. 2).[10] Most recently, Hou and coworkers reported the enantioselective alkylation of 2-substituted pyridines with 
unactivated, terminal alkenes using a chiral, half-sandwich scandium complex. (Figure 2.1, eq. 3).[11] 
Figure 2.1 TM-catalyzed asymmetric intermolecular hydroheteroarylation reactions previously reported in the 
literature 
While the work of Hartwig and Hou provides a powerful proof of concept, room for complementary 
asymmetric HH methods remain. Specifically, we sought to expand the scope of the olefin coupling partner. 
Hartwig’s HH reaction is demonstrated only with the strained cyclic alkene, norbornene,[10] and Hou’s pyridine 
alkylation appears limited to relatively unfunctionalized, electron-neutral alkenes.[11] Herein, we describe a Rh(I)-
catalyzed asymmetric alkylation of benzoxazoles with acrylate derivatives (Figure 2.2, eq. 4). To our knowledge, 
this work represents the first example of an enantioselective, transition-metal-mediated, intermolecular HH of 
acyclic, electron-deficient alkenes. Moreover, the described reaction makes products of potential medicinal value; 
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Figure 2.2 Our HH reaction of benzoxazoles and α-substituted acrylates and precedent inspiring its development 
We found inspiration for the described HH reaction in chemistry developed by Chang et al.[4j] This group 
reported the HH of acrylates and acrylate derivatives with benzheterocycles or pyridine oxides (Figure 2.2, eq. 5). 
Chang et al. invoke catalysis by a Rh(I)–acetate species: acetate counterion mediates C–H activation, while liberated 
acetic acid protonates an eventual C–Rh bond (Figure 2.2, eq. 6). We envisioned that use of a substituted acrylate in 
a system related to Chang’s would enable the asymmetric preparation of branched products (Figure 2.2, eq. 7). 
Notably, the Rh(I)–dppe system used by Chang lends itself to enantioselective modification: in contrast to relatively 
scarce chiral cyclopentadienyl ligands ubiquitous in Rh(III) catalysis,[6d–e,6h] chiral bisphosphine ligands abound.[13]   
Despite the overt similarity between the known and proposed reactions, several complications could accompany 
the envisioned asymmetric method. The mechanism proposed by Chang invokes protonation of Rh–enolate II 
(Figure 2.2).[4j] While protonation of C-bound II could provide enantioenriched products, protonation or ligand 
exchange of O-bound III at oxygen would give racemic product. Additionally, β-H elimination and dissociation of 
resultant conjugated alkene would furnish undesired Heck product.[4j] Indeed, success of Hartwig’s and Hou’s 
chemistry may be understood in the light of these anticipated difficulties; the privileged nature of norbornene in eq. 
2 (Figure 2.1) likely derives in part from the fact that presumed intermediate I cannot undergo β-H elimination. 
Hou’s pyridine alkylation is also presumably more insulated from β-H elimination than a Rh(I) system, since the 
enhanced thermodynamic stabilization of metal–hydrogen bonds over metal–carbon bonds is smaller for early TMs 
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While we were aware that the described pitfalls could plague our desired reaction with low stereo- or product- 
selectivity, work by Reetz, Genet and others offered hope that these obstacles would not be insurmountable.[15] 
These groups report that a Rh(I)–chiral bisphosphine system mediates the asymmetric hydroarylation of α-
substituted acrylates with boronic acid derivatives (Figure 2.2, eq. 8). Importantly, this reaction is presumed to 
intercept analogous Rh–enolate intermediate IV.[15b-d] Similar opportunities for stereochemical scrambling or Heck 
reactivity exist for IV as for our presumed Rh–enolate II. Yet these pathways must not be competitive in the 
described systems, since saturated products are obtained in good to excellent enantioselectivities.[15] These groups 
invoke asymmetric protonation of Rh–enolate IV or O-bound isomer to explain high product enantioselectivities,[15-
16] but aside from Genet et al.,[15e] none provide rigorous mechanistic evidence in favor of this claim. 
2.3 Results and discussion 
2.3.1 Initial reaction optimization with [Rh(cod)OAc]2 
Encouraged that our asymmetric HH could succeed, we decided to begin by investigating mechanistic aspects 
of the parent, achiral reaction (Figure 2.2, eq. 5). The first question we sought to address was the role of the CsOAc. 
If, as Chang and coworkers postulated, CsOAc serves to generate a Rh(I)–acetate catalyst in situ, then perhaps the 
same reactivity could be accomplished with a premade Rh(I)–acetate catalyst. Chatani and coworkers have indeed 
observed that [Rh(cod)OAc]2 can be used in the place of a KOAc–[Rh(cod)Cl]2 system in the directed 
hydroarylation of acrylates with 8-aminoquinoline-derived benzamides.[17,18] We prepared [Rh(cod)OAc]2 by 
treating [Rh(cod)Cl]2 with KOAc in refluxing acetone according to a known procedure.[19] Recrystallization from 
EtOAc provided X-Ray quality crystals of the air-stable, orange solid. These were characterized by X-Ray 
crystallography thanks to Dr. Kevin Martin Oberg to provide what we believe is the first reported crystal structure of 
the complex (Figure 2.3).[20]  
Figure 2.3 X-Ray crystal structure of [Rh(cod)OAc]2 
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As predicted, [Rh(cod)OAc]2 performs with equal efficiency as Chang’s in situ generated catalyst in the HH of 
several benzheterocycles 1 with tert-butyl acrylate (Table 2.1). CsOAc thus appears to serve primarily as an acetate 
source in Chang’s chemistry. 
Table 2.1 HH using Chang’s established conditions (red)[Ref. 4j] or [Rh(cod)OAc]2 (blue)[1-2] 
[1]To ensure uniformity for comparison, all reactions were performed by the first author. [2]Yields were determined 
with respect to 4,4’-di-tert-butylbiphenyl (DTBB) by 1H NMR of the reaction mixture. 
With [Rh(cod)OAc]2 in hand, we screened the asymmetric HH of ethyl methacrylate (3a) and 4-
methylbenzoxazole (1c) (Table 2.2), since this heterocycle proved most reactive in the achiral reaction with tert-
butyl acrylate (Table 2.1). Ligands resembling dppe were chosen at the outset. In PhMe at 120 °C, 1c and 3a react in 
the presence of a Rh(I)–prophos (L1) catalyst to deliver α-substituted product 4ca in quantitative yields and 29% ee 
(Table 2.2, entry 1). Ees remain modest with Chiraphos (L2) and Me-Duphos (L3) (entries 2 and 3). Significant 
improvement in ee is achieved with Binap (L4), but yields of 4ca suffer (entry 4). Since bite angle is known to have 
a pronounced effect on reaction selectivity and efficiency,[21] we examined Binap derivatives, Synphos (L5, entry 5) 
and Segphos (L6, entry 6), whose bite angles we hoped would compare more favorably to dppe.[22-23] Gratifyingly, a 
Rh(I)–Segphos system delivers product 4ca in acceptable 56% yield, and good selectivity (85% ee, entry 6). A two-
fold increase in acrylate concentration further increases reactivity, providing comparable yields in 24 h to what is 
obtained in 60 h with lower acrylate concentrations (entries 6-9). Concurrently, a solvent and temperature screen 
(entries 9-17) revealed acetonitrile (CH3CN) to be optimal for selectivity (95% ee, entry 11). Combining results, 
execution of the HH reaction in CH3CN with 8 equivalents of acrylate 3a and 5 mol % [Rh(cod)OAc]2 provides 
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Table 2.2 Initial reaction optimization 
 
entry ligand solvent equiv 3a T (°C) time (h)  4ca (%)[1] ee (%)[2] 
1 L1 PhMe 4 120 60 100 29 
2 L2 PhMe 4 120 60 95 -47 
3 L3 PhMe 4 120 60 39 57 
4 L4 PhMe 4 120 60 9 -78 
5 L5 PhMe 4 120 60 20 84 
6 L6 PhMe 4 120 60 56 85 
7 L6 PhMe 4 120 24 19 89 
8 L6 PhMe 6 120 24 29 85 
9 L6 PhMe 8 120 24 58 77 
10 L6 PhMe 4 100 24 17 88 
11 L6 CH3CN 4 100 24 15 95 
12 L6 TFE 4 100 24 < 5 16 
13 L6 DCE 4 100 24 < 5  95 
14 L6 DME 4 100 24 6 91 
15 L6 DMF 4 100 24 22 88 
16 L6 PhCF3 4 100 24 10 95 
17 L6 o-DCB 4 160 24 7 17 
18[3] L6 CH3CN 8 100 24 58 95 
[1]Determined with respect to DTBB by LC analysis of the crude reaction mixture on a chiral stationary phase. 
[2]Determined at the same time as percent yield by LC analysis of the crude reaction mixture on a chiral stationary 
phase. [3]Reaction conducted with 5 mol % [Rh(cod)OAc]2 and 10 mol % L6. 
2.3.2 Mechanistic investigations of achiral system  
Although we were pleased with this result, we anticipated that reaction efficiency would need to be further 
improved in order to extend the substrate scope to less reactive heterocycles. For instance, when benzoxazole 1a is 
reacted under the conditions shown in entry 2 of Table 1 (which provide nearly quantitative yields of 4ca), no 
discernable product 4aa is obtained (eq. 9). Before refining our conditions, we sought to understand what made 4-
methylbenzoxazole (1c) so much more reactive than its unsubstituted- or 6-substituted counterparts (Table 2.1, 1a–
1b and 1d). Yields displayed in Table 2.1 fail to adequately capture this striking reactivity difference—while 
reaction of 1c is complete in 3h, reaction of 1a, 1b and 1d stall at about 50% after 60 h. To gain insight into this 
disparate reactivity, we performed two competition experiments—one between 1b-D and 1c-H (eq. 10 and Figure 
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From the former, the following significant observations are made: (a) crossover substrates 1b-H and 1c-D are 
observed by 1H and 2H NMR (Figure 2.4a) (b) deuterium is incorporated into the alkyl backbone of both products 
2b and 2c (eq. 10) and (c) deuterium is incorporated predominantly at the β-position of both products (eq. 10). From 
this data, we propose a mechanistic cycle similar to that offered by Chang et al. (Figure 2.5b):[4j,25] A Rh(I)–acetate 
catalyst mediates reversible C–H activation of heteroarene 1 (observation a) to provide Rh–heteroaryl complex V. 
Migratory insertion (MI) across the terminal acrylate (R = H) furnishes Rh–enolate VI, which isomerizes via a β-H 
elimination, hydrorhodation sequence to heterobenzyl-Rh VIII (observation c). Protonation appears to occur 
predominantly from VIII (or the N-bound isomer, see XIV, Figure 2.8). Protonation likely proceeds via an outer 
sphere mechanism (observation b), but an inner sphere mechanism after D–H exchange cannot be ruled out. 
   
 
Figure 2.4 (a) 1H and 2H NMR of competition experiment between 1c-H and 1b-D (eq. 10) implicates reversible C–

























































[Rh(cod)OAc]2 (2 mol %)
(S,S)-chiraphos (4 mol %)
MeR R
PhMe, 120 °C, 60h
4ca: R = Me: 95%, -47% ee
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Competition between 1b-H and 1c-H provides further mechanistic insights (eq. 11). When reactive 1c and 
sluggish 1b (Chart 1) are subjected to the standard conditions, products 2b and 2c form in roughly equal rates (eq. 
11). We rationalize the identical rates of formation of 2b and 2c in one of two ways, both of which invoke the 
different ligating abilities of 1b and 1c. Given that C–H activation is reversible, one explanation assumes that there 
exists one or more irreversible steps before the turnover-limiting step (TLS) of sluggish substrate 1b.[26] In the 
context of the mechanism shown in Figure 2.4, we assume that MI is irreversible, and therefore product determining, 
and that protonation of 1b-derived intermediates VI or VIII is turnover limiting. Sluggish protonation of 1b-derived 
VI or VIII is understood by invoking coordination of the heterocycle to rhodium in 1b-derived intermediate VI. 
Ligation blocks a free coordination site necessary for either protonation of VI or isomerization to VIII via β-H 
elimination. While unhindered azoles such as 1b, 1a and 1d can presumably bind in the fashion described, A[1,3]- 
strain would disfavor analogous coordination of 1c-derived IX, accelerating the reactivity of 1c relative to its 
unsubstituted counterparts. Indeed, 15N NMR studies suggest that bulky substitution adjacent to the coordinating 
nitrogen of various oxazoles impedes their coordination to Rh(II)-complexes.[27] To sum up, then, so long as the C–
H activation, MI sequence proceeds at roughly equal rates for both substrates, products 2b and 2c will form in a one-
to-one ratio, since all catalyst will eventually funnel to 1b-derived VI.  
In perhaps a more simple explanation, strongly coordinating 1b (and 1a and 1d) but not weakly coordinating 1c 
acts as a competitive ligand toward important intermediates on or off the catalytic cycle, slowing catalysis of both 
1b and 1c. 
Although it would be difficult to discriminate between these two explanations—one invoking an intramolecular 
coordination event and one invoking an intermolecular coordination event—both suggest similar avenues for 
reaction optimization. Specifically, if deleterious coordination of the heteroarene were responsible for low reactivity 
of 1a–1b and 1d, then perhaps coordination could be discouraged by increasing the bulk of the bisphosphine ligand. 
We were optimistic that increasing ligand bulk might offer additional advantages. A congested coordination 
environment could also encourage a difficult MI event for steric reasons, since MI necessarily reduces the metal 
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2.3.3 Optimization of the asymmetric hydroheteroarylation reaction with second generation ligands 
To this end, we sought to further optimize the reaction of ethyl methacrylate (3a) and 1c by screening bulky 
Segphos derivatives (Table 2). While DTBM-Segphos (L8) is fairly unreactive (entry 3), DM-Segphos (L7) 
improves yields by about 20% relative to Segphos (Table 2, entries 1 vs. 2). With the arene held constant, 
exploration of the phosphine backbone revealed CTH-(R)-Xylyl-P-Phos (L11) to be a superior ligand.[29] It provides 
quantitative yield of product 4ca in excellent enantioselectivity after 24 h (entry 6). A control reaction confirms that 
the acetate counterion is crucial for reactivity—no product is obtained under optimal conditions when [Rh(cod)Cl]2 
is used.[30] 
Table 2.3 Reaction optimization with second generation, bulky bisphospine ligands  
 
entry ligand Ar 4ca (%)[1] ee (%)[2] 
1 L6 Ph 58 95 
2 L7 m-xylyl 79 93 
3[3] L8 DTBM 23 57 
4 L9 m-xylyl 33 93 
5 L10 m-xylyl 29 92 
6 L11 m-xylyl > 98 95 
[1]–[2]See footnotes for Table 2.2. [3]With 2 mol % [Rh(cod)OAc]2, 4 mol % L8, 4 equiv 3a in PhMe at 120 °C for 60 
h: these conditions give 4ca in 56% yield and 85% ee when L6 is used as a ligand. 
2.3.4 Scope of the asymmetric hydroheteroarylation reaction 
With these second generation conditions in hand, we sought to examine the substrate scope of our HH reaction 
(Table 2.4).[31] Variation of the ester group provides products 4ca–4cc in excellent yields and selectivities. 
Methacrylonitrile (3d) participates in moderate yield and good enantioselectivity. The HH reaction is also tolerant of 
diverse acrylate backbones, although α-substitution appears crucial—racemic product 4ce is obtained in low yield 
from the reaction of 1c and ethyl crotonate (3e). Acrylates with benzyl, n-butyl and sterically bulky isobutyl 
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the opportunity for β-H elimination into the alkyl backbone. Dimethyl itaconate (3i) provides good yields of 
functionalized product 4ci albeit in modest enantioselectivity. Acrylate 3j containing a protected alcohol reacts 
without difficulty to give silyl ether 4cj in excellent enantioselectivity. 
Table 2.4 Scope of the Rh(I)–xylyl-P-Phos-catalyzed HH of benzoxazoles and methacrylate derivatives[1-2] 
[1]Isolated yields after column chromatography on silica gel. [2]Ees of isolated products determined by LC analysis 
on chiral stationary phase. [3]Reaction run for 24 h. [4]Yield determined with respect to DTBB by LC analysis of the 
crude reaction mixture on a chiral stationary phase. [5]Reaction run for 80 h. [6]Yield determined with respect to 
DTBB by 1H NMR of the crude reaction mixture.  [7]Ee determined by LC analysis of the crude reaction mixture on 
a chiral stationary phase.  
Notably, it was found that addition of 25 mol % CsOAc is necessary to promote reactivity for these more 
hindered acrylates—indeed, no product is obtained from the reaction of benzyl-substituted 3f in its absence (Table 
2.4).[32] While the beneficial effect of CsOAc is not fully understood, acetate rather than cesium ion appears to be 
responsible for the yield improvement, since no product is obtained from the reaction of 3f and 1c when CsI is used 
in the place of CsOAc.  
Finally, and much to our gratification, variation of the benzoxazole backbone is possible with bulky P-Phos 
ligand L11. Unsubstituted benzoxazole 1a reacts smoothly; chloro and fluoro products 4ea–4fa are assembled in 
high ees albeit in diminished yields. Isomeric methoxy products 4ga–4ha are obtained in moderate yield and 
moderate to high enantioselectivities. While addition of 25 mol % CsOAc also appears to accelerate reactions with 
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The HH reaction is not without limitations. Acrylates substituted with secondary alkyl (3k) or aryl (3l) groups 
do not participate effectively, nor do α,β-disubstituted acrylates (3o and 3p) or acrylates containing β-leaving groups 
(3m and 3n) (Figure 2.5). Amide 3q, acetamidoacrylates 3r and 3s, 3-methyl-3-buten-2-one (3t) and thioester 3u 
etiher do not react under conditions using CTH-(R)-xylyl-P-Phos (L11) or DM-segphos (L7) or react to give 
products 4 in poor yields (Figure 2.5). Exploration of heteroarene coupling partner reveals very electron-deficient 
benzoxazole 2i to be a poor substrate in the HH reaction with ethyl methacrylate (Figure 2.6). Benzothiazole 2j 
provides product in low yields despite 4-methyl substitution. Oxazoles 2k and 2l, which bear bulky substituents at 
the 4-position to discourage undesired coordination, also react sluggishly. Finally, electron-deficient oxazole 2m 
provides product 4 only in low yields. Although the relative reactivity of benzoxazoles 2 is not entirely understood, 
substrate pKa and steric environment at nitrogen appear to contribute. 
 
Figure 2.5 Acrylate derivatives that do not provide significant product in the HH reaction with benzoxazoles using 
CTH-(R)-xylyl-P-Phos (L11) or DM-segphos (L7) 
Figure 2.6 Benzoxazoles and oxazoles do not provide significant product in the HH reaction with ethyl methacrylate 
CTH-(R)-xylyl-P-Phos (L11) or DM-segphos (L7)  
2.3.5 Mechanistic investigations into origin of enantioselectivity 
At this point in our studies, we wanted to better understand the origin of enantioselectivity of our HH reaction. 
Asymmetric protonation of a rhodium enolate (e.g. IV or O-bound isomer, eq. 8, Figure 2.2) is classically invoked 
as the enantiodetermining step of the Rh(I)–bisphosphine mediated addition of boronic acids to α-substituted 
acrylates, although mechanistic evidence is sparse.[15] We chose to test plausibility of this enantiodetermining step 
with a labeling study using deuterated 1c (1c-D) (Figure 2.7, eq. 12). Were our HH mechanism to proceed via 
protonation of a rhodium–enolate (e.g. II or III, Figure 2.2; or VI, Figure 2.4b), then we should see 2H-
incorporation at the α-position of product 4ca, since 1c is the terminal proton source. Contrary to this expectation, 
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incorporated exclusively at the β-position (eq. 12). 1c is recovered with 33% H incorporation, consistent with a 
reversible C–H activation event. The proton source responsible for formation of 1c-H in eq. 12 is presumably 
solvent: indeed, when the experiment is repeated in CD3CN, virtually no H–D exchange in 1c-D is observed (eq. 13). 
All 2H from 1c-D is accounted for in product 4ca, since CH3CN cannot compete as a proton source (eq. 13). β-
deuterium incorporation in 4ca does not likely arise from in situ generation and subsequent preferential reaction of 
β-deutero-3a, since reciprocal reaction of 1c-H and 3b-d8 gives 4ba with 1H-incorporation at the β-position 
exclusively (eq. 14). 
Figure 2.7 Labeling studies suggest that enolate protonation is not enantiodetermining 
These labeling studies provide considerable insight into the reaction mechanism. First, they give grounds for 
dismissal of several possible elementary steps. For instance, protonation of a rhodium enolate cannot be 
enantiodetermining, as protonation takes place predominantly at the β- rather than the α-position. 
The labeling study also seems to contradict a mechanism involving migratory insertion of a Rh(III)–heteroarene 
(in a 3,2 sense) or a Rh(III)–hydride (in a 2,3 sense) across acrylate 3 followed by reductive elimination to form a 
C–H or C–C bond respectively—this mechanism, too, would deliver products deuterated at the α- not the β- 
position.[33] To account for the results of our labeling experiment, then, we propose a mechanism analogous to that 
proffered by Chang and coworkers for the hydroheteroarylation of terminal acrylates (Figure 2.4, R  H).[4j] 
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undergoes MI across the acrylate. At this point, a β-H elimination, hydrorhodation sequence isomerizes resultant 
Rh–enolate VI to alkyl-Rh VIII, which is protonated by acetic acid, regenerating a rhodium–acetate complex. 
We believe that the proposed isomerization event is crucial for the high enantioselectivities obtained in our 
reaction. In our preferred mechanism, enantiodetermining MI delivers C-bound Rh–enolate X in a stereodefined 
fashion (Figure 2.8). One might imagine that C-bound X could equilibrate with O-bound rhodium isomer XI. 
Protonation or ligand exchange of XI on oxygen would deliver racemic product, and ees would suffer to the extent 
that this path is operative. Isomerization of Rh–enolate X to isomer XII, then, insulates the α-stereocenter from 
epimerization, so long as isomerization is stereospecific. Stereospecificity is guaranteed if the β-H elimination, 
hydrorhodation steps take place from the same face of alkene XIII, or said another way, if Rh–H intermediate XIII 
stays bound to the alkene in a sigma fashion. Indeed, β-H-elimination, hydrometalation sequences mediated by late 
transition-metals have been shown to preserve with high fidelity the stereochemistry set by MI events.[5m]  
Figure 2.8 Rationale for isomerization of a rhodium enolate intermediate 
This mechanism may also help explain why α-substituted acrylates are privileged substrates for our HH reaction 
and perhaps even for the Rh(I)-bisphosphine mediated asymmetric hydroarylation reported by Darses and others.[15] 
When an α-substituted acrylate is used, C-bound Rh–enolate X is tetrasubstituted (Figure 2.8), and O-bound isomer 
XI experiences significant allylic strain, either between the ester OR group and the heterobenzylic carbon (red, XI-
1) or between rhodium and the α-R substituent (blue, XI-2). Sterics may thus discourage formation of XI and 





















































the heterobenzyl complex. Protonation or ligand exchange may be facilitated by isomerization to Rh–enamido 
complex XIV.[34] 
Final evidence for our proposed mechanism is provided by epimerization studies (Figure 2.9). We wanted to 
know why the reaction of 1c appeared significantly more selective than the reaction of other benzoxazole substrates, 
particularly 1h. We speculated that epimerization over the long reaction time might be partially responsible, but we 
struggled to rationalize why 4ha would epimerize more quickly than other products: the most simple racemization 
pathway that can be imagined is deprotonation-reprotonation of the α-stereocenter by an acetate–acetic acid couple. 
Yet electronics of the benzoxazole backbone should not affect acidity of the remote stereocenter. Nevertheless, we 
resubjected low (4ha)-, intermediate (4ga)- and high (4ca)-ee products to the reaction of 1c and an appropriate 
acrylate (eq. 15-17). When low ee-product 4ha is resubjected to the reaction of 1c and 3a under standard conditions, 
it is indeed found to epimerize to 50% ee (eq. 15). In contrast, the ee of product 4ca drops to only 93 % ee when it is 
resubjected to the reaction of 1c and benzyl methacrylate 3c under identical conditions (eq. 17).[35] Yet epimerization 
does not appear solely responsible for the low ees of 4ha, since intermediate-ee product 4ga also shows significant 
stereochemical scrambling under the reaction conditions (eq. 16). 
Figure 2.9 Epimerization experiments of 4ha, 4ga and 4ca 
That rates of epimerization of product 4 depend crucially on the benzoxazole backbone challenge an 
epimerization mechanism via traditional, base-assisted deprotonation of the α-stereocenter. Tenuousness of this 
racemization pathway is reinforced by the fact that product 4ha epimerizes at the same rate in the presence or 
[Rh(cod)OAc]2 
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absence of added base (eq. 15)[36] and that CsOAc alone fails to epimerize product 4ha even after prolonged heating 
(data not shown). 
In light of insights gained from labeling studies in eq. 12-14, we wondered whether epimerization takes place 
by the microscopic reverse of the mechanism proposed in Figure 2.8: coordination of the benzoxazole nitrogen to 
rhodium acidifies the heterobenzylic hydrogen of product 4, which is abstracted by acetate (Figure 2.10, step 1).[37] 
Resultant Rh–enamido complex XVI, which is in equilibrium with C-bound XVII (step 2), isomerizes back into the 
acrylate backbone via a series of β-H-elimination, hydrorhodation events (steps 3-5) to eventually give O-bound 
Rh–enolate XX. Enolate XX is shown as, but need not exist as, the rhodacycle.  Protonation or ligand exchange of 
XX at oxygen epimerizes the α-stereocenter of product 4 (step 6).[38] While intermediate XVII is shown with a 
specific stereochemistry at the carbon bearing rhodium, this is only intended to illustrate that no stereochemical 
scrambling of the α-stereocenter occurs prior to formation of O-bound XX if alkene XVIII remains coordinated to 
rhodium (i.e. the stereochemistry of the starting material is relayed to the stereochemistry of C-bound XIX). 
Figure 2.10 Proposed epimerization mechanism 
We tested credence of this mechanism by treating product 4ha (75% ee) with [Rh(cod)OAc]2 and CTH-(R)-
xylyl-P-Phos in CD3CN (Figure 2.11, eq. 18), since we knew CD3CN to be a competent proton source (Figure 2.7, 
eq. 12). If epimerization were occurring via a typical deprotonation-reprotonation sequence at the α-carbon, then we 
should see deuterium incorporation at the α-position of product 4ha. On the other hand, if epimerization mechanism 






























































In accord with our hypothesis, 4ha is isolated from the reaction in eq. 18 in 20 % ee with significant deuterium 
incorporation at the α-position and predominant deuterium incorporation at the β-position (Figure 2.11, eq. 18). 
Figure 2.11 Epimerization-labeling studies 
While this data cannot unequivocally debunk a mechanism by which deuteration at the α- and β-positions occur 
by independent deprotonation-reprotonation events at vicinal carbons, the level of deuterium incorporation at the α-
position of product 4ca strongly suggests that the two incorporation events are coupled by a common intermediate. 
Specifically, 22% deuterium at the α-position of 4ca does not nearly account for a 55% loss in ee of 4ca (Scheme 
2.11, eq. 18).[39] Thus, 4ca must epimerize by at least one other mechanism besides protonation. We propose that 
Rh–enolate intermediate XX has two opportunities to scramble α-stereochemistry (Figure 2.10). It can, as already 
discussed, protonate or undergo ligand exchange on oxygen to give enantiomeric product (Figure 2.10, step 6). Yet 
protonation is not necessary for epimerization to occur. To the extent that the α-stereochemistry of C-bound XIX is 
lost in O-bound XX, then isomerization back to the C-bound isomer should be able to deliver diastereomeric 
complex XXI in which α-stereochemistry is inverted (Figure 2.10, step 7). A reverse sequence of elimination and 
addition events relays XXI to enantiomeric product (Figure 2.10, step 8). 
We wondered how the epimerization mechanism depicted in Figure 2.10 could account for the very different 
fates of low-ee product 4ha and high-ee product 4ca when they are resubjected to our Rh–bisphopshine system. 
Interestingly, when highly enantioenriched product 4ca (95% ee) is treated with rhodium and ligand under 
conditions identical to those described for 4ha, 4ca also deuterates considerably at the β-position (Figure 2.11, eq. 
19). In contrast to 4ha, however, product 4ca epimerizes quite slowly (to 91%) even at high dimer loading, and it 
shows no discernable 2H incorporation at the α-position. We provide two possible explanations to account for the 
data in eq. 18-19, but alternatives are possible. As illustrated in Figure 2.10, C–H activation of 4 gives Rh–enamido 








































XVI such that a rapid backward reaction—protonation of XVI—outcompetes isomerization into the acrylate 
backbone. 
An alternative explanation invokes differential stability of 4ha and 4ca Rh–enolate complexes XX (Figure 2.10). 
Whereas coordination of the heterocyclic nitrogen to rhodium could stabilize 4ha-derived Rh–enolate XX, A[1,3]-
strain would prevent analogous stabilization of 4ca-derived XX. In either case, relative coordinating abilities of 4ca 
and other benzoxazoles appear to crucially influence product epimerization rates. If this is true, then our bulky P-
Phos ligand may serve an additional service: it may discourage ligation-promoted racemization pathways. 
2.4 Summary  
In summary, mechanistic insights gained from a known reaction of heterocycles and tert-butyl acrylate[4j] 
enabled development of an asymmetric, hydroheteroarylation reaction of benzoxazoles and α-substituted acrylates. 
The reaction is mediated by a rhodium–acetate precatalyst and bulky bisphosphine ligand, CTH-(R)-xylyl-P-Phos, 
and it delivers diverse elaborated benzoxazole products in moderate to excellent yields and good to excellent 
enantioselectivities. Mechanistically, the reaction is thought to proceed via a C–H activation, MI and protonation 
sequence in which acetate serves as a proton shuttle. Labeling studies implicate MI as a possible enantiodetermining 
step, after which stereospecific isomerization to a Rh–heterobenzyl complex insulates the newly formed stereocenter 
from epimerization. Products that are good ligands for rhodium can epimerize by a reverse sequence: coordination 
and subsequent C–H activation at the heterobenzylic position provides a Rh–enamido complex. A series of β-H 
elimination-hydrorhodation events relays the enamido complex to an O-bound rhodium enolate, in which α-
stereochemistry is lost. Our proposed mechanism differs importantly from those implicated in studies describing the 
related Rh(I)–bisphosphine-mediated hydroarylation of α-substituted acrylates with boronic acids.[15] These studies 
invoke protonation of a rhodium enolate as the enantiodetermining step of the reaction. Since little mechanistic 
evidence is provided in these studies, it is conceivable that an isomerization pathway such as ours is operative in 
these systems. Finally, a bulky bisphosphine ligand is found to be crucial for reactivity and selectivitity in our HH 
reaction, as it likely discourages deleterious coordination of benzoxazole substrates to on- or off-cycle intermediates, 
accelerates a difficult MI step and discourages coordination-initiated epimerization. In short, careful mechanistic 
analysis has enabled the development of an efficient and highly selective catalytic, asymmetric HH of readily 







[1] Text and figures for this chapter have been adapted with permission from Filloux, C. M.; Rovis, T. J. Am. 
Chem. Soc. 2015, 137, 508 – 517. Can be found online at: http://pubs.acs.org/doi/abs/10.1021/ja511445x. 
[2]  For selected reviews and examples of catalytic, asymmetric alkylation of heteroarenes mediated by chiral acids, 
see:  
 (a) Bandini, M.; Melloni, A.; Umani-Ronchi, A. Angew. Chem., Int. Ed. 2004, 43, 550 – 556.  
 (b) Bandini, M.; Melloni, A.; Tommasi, S.; Umani-Ronchi, A. Synlett 2005, 1199 – 1222.  
 (c) Evans, D. A.; Fandrick, K. R.; Song, H. J.; Scheidt, K. A.; Xu, R. J. Am. Chem. Soc. 2007, 129, 10029 –
10041.  
 (d) Alexakis, A.; Bac̈kvall, J. E.; Krause, N.; Pàmies, O.; Diéguez, M. Chem. Rev. 2008, 108, 2796 – 2823.  
 (e) You, S. L.; Cai, Q.; Zeng, M. Chem. Soc. Rev. 2009, 38, 2190 – 2201.  
 (f) Boersma, A. J.; Feringa, B. L.; Roelfes, G. Angew. Chem. Int. Ed. 2009, 48, 3346 – 3348.  
 (g) Terrasson, V.; Marcia de Figueiredo, R.; Campagne, J. M. Eur. J. Org. Chem. 2010, 2635 – 2655.  
 (h) Duan, S.; An, J.; Chen, J.; Xiao, W. Org. Lett. 2011, 13, 2290 – 2293.  
 (i) Chauhan, P.; Chimni, S. S. RSC. Adv. 2012, 2, 6117 – 6134. 
 (j) Huo, H.; Fu, C.; Harms, K.; Meggers, E. J. Am. Chem. Soc. 2014, 136, 2990 – 2993. 
[3] For reviews of transition-metal-catalyzed hydroheteroarylation, see:  
 (a) Lewis, J. C.; Bergman, R. G.; Ellman, J. A. Acc. Chem. Res. 2008, 41, 1013 – 1025.  
 (b) Colby, D. A.; Bergman, R. G.; Ellman, J. A. Chem. Rev. 2010, 110, 624 –655. 
[4]  For selected examples of non-asymmetric, transition-metal-catalyzed hydroheteroarylation, see:  
 (a) Tan, K. L.; Bergman, R. G.; Ellman, J. A. J. Am. Chem. Soc. 2001, 123, 2685 – 2686.  
 (b) Tan, K. L.; Bergman, R. G.; Ellman, J. A. J. Am. Chem. Soc. 2002, 124, 3202 – 3203. 
 (c) Tan, K. L.; Bergman, R. G.; Ellman, J. A. J. Am. Chem. Soc. 2002, 124, 13964 – 13965.  
 (d) Baran, P. S.; Guerrero, C. A.; Corey, E. J. J. Am. Chem. Soc. 2003, 125, 5628 – 5629.  
 (e) Ferreira, E. M.; Stoltz, B. M. J. Am. Chem. Soc. 2003, 125, 9578 – 9579.  
 (f) Liu, C.; Han, X.; Wang, X.; Widenhoefer, R. A. J. Am. Chem. Soc. 2004, 126, 3700 – 3701.  
 (g) Nakao, Y.; Kashihara, N.; Kanyiva, K. S. Hiyama, T. Angew. Chem. Int. Ed. 2010, 122, 4553 – 4454.  
 (h) Nakao, Y.; Yamada, Y.; Kashihara, N.; Hiyama, T. J. Am. Chem. Soc. 2010, 132, 13666 – 13668.  
 (i) Jiao, L.; Herdtweck, E.; Bach, T. J. Am. Chem. Soc. 2012, 134, 14563 – 14572.  
 36 
 (j) Ryu, J.; Cho, S. H.; Chang, S. Angew. Chem. Int. Ed. 2012, 51, 3677 – 3681. 
[5] For selected reviews and examples of asymmetric, transition-metal-catalyzed hydroarylation of olefins with 
activated arenes, see:  
 (a) Hayashi, T.; Ueyama, K.; Tokunaga, N.; Yoshida, K. J. Am. Chem. Soc. 2003, 125, 11508 – 11509.  
 (b) Shintani, R.; Ueyama, K.; Yamada, I.; Hayashi, T. Org. Lett. 2004, 6, 3425 – 3427.  
 (c) Tietze, L. F.; Ila, H.; Bell, H. P. Chem. Rev. 2004, 104, 3453 – 3561.  
 (d) Hayashi, T.; Tokunaga, N.; Okamoto, K.; Shintani, R. Chem. Lett. 2005, 34, 1480 – 1481.  
 (e) Nakao, Y.; Chen, J.; Imanaka, H.; Hiyama, T.; Ichikawa, Y.; Duan, W.; Shintani, R.; Hayashi, T. J. Am. 
Chem. Soc. 2007, 129, 9137 – 9143.  
 (f) Edwards, H. J.; Hargrave, J. D.; Penrose, S. D.; Frost, C. G. Chem. Soc. Rev. 2010, 39, 2093 – 2105.  
 (g) Menard, F.; Perez, D.; Roman, D. S.; Chapman, T. M.; Lautens, M. J. Org. Chem. 2010, 75, 4056 – 4068.  
 (h) Nishimura, T.; Wang, J.; Nagaosa, M.; Okamoto, K.; Shintani, R.; Kwong, F.; Yu, W.; Chan, A. S. C.; 
Hayashi, T. J. Am. Chem. Soc. 2010, 132, 464 – 465.  
 (i) Tian, P.; Dong, H.; Lin, G. ACS Catal. 2012, 2, 95 – 119.  
 (j) Howell, G. P. Org. Process Res. Dev. 2012, 16, 1258 – 1272.  
 (k) Brawn, R. A.; Guimarães, C. R. W.; McClure, K. F.; Liras, S. Org. Lett. 2013, 15, 3424 – 3427.  
 (l) Liu, S.; Zhou, J. Chem. Commun. 2013, 49, 11758 – 11760.  
 (m) Mei, T.; Werner, E. W.; Burckle, A. J.; Sigman, M. S. J. Am. Chem. Soc. 2013, 135, 6830 – 6833 
(functionally an asymmetric hydroarylation reaction).  
 (n) So, C. M.; Kume, S.; Hayashi, T. J. Am. Chem. Soc. 2013, 135, 10990 – 10993. 
[6]  For selected reviews and examples of transition-metal-catalyzed, asymmetric hydroarylation of olefins via 
directed C–H activation, see:  
 (a) Aufdenblatten, R.; Diezi, S.; Togni, A. Monatsh. Chem. 2000, 131, 1345 – 1350.  
 (b) Thalji, R. K.; Ellman, J. A.; Bergman, R. G. J. Am. Chem. Soc. 2004, 126, 7192 – 7193.  
 (c) Tsuchikama, K.; Kasagawa, M.; Hashimoto, Y.; Endo, K.; Shibata, T. J. Organomet. Chem. 2008, 693, 
3939 – 3942.  
 (d) Hyster, T. K.; Knörr, L.; Ward, T. R.; Rovis, T. Science 2012, 338, 500 – 503.  
 (e) Ye. B.; Cramer, N. Science 2012, 338, 504 – 506.  
 (f) Pan, S.; Shibata, T. ACS Catal. 2013, 3, 704 – 712.  
 (g) Zheng, C.; You, S. RSC Adv. 2014, 4, 6173 – 6214.  
 (h) Ye, B.; Donets, P. A.; Cramer, N. Angew. Chem. Int. Ed. 2014, 53, 507 – 511. 
 37 
[7]  Wiedemann, S. H.; Lewis, J. C.; Ellman, J. A.; Bergman, R. G. J. Am. Chem. Soc. 2006, 128, 2452 – 2462. 
[8] (a) Wilson, R. M.; Thalji, R. K.; Bergman, R. G.; Ellman, J. A. Org. Lett. 2006, 8, 1745 – 1747.  
 (b) Rech, J. C.; Yato, M.; Duckett, D.; Ember, B.; LoGrasso, P. V.; Bergman, R. G.; Ellman, J. A. J. Am. Chem. 
Soc. 2007, 129, 490 – 491.  
 (c) Tsai, A. S.; Wilson, R. M.; Harada, H.; Bergman, R. G.; Ellman, J. A. Chem. Commun. 2009, 3910 – 3912. 
[9] Pan, S.; Ryu, N.; Shibata, T. J. Am. Chem. Soc. 2012, 134, 17474 – 17477. 
[10]  Sevov, C. S.; Hartwig, J. F. J. Am. Chem. Soc. 2013, 135, 2116 – 2119. 
[11]  Song, G.; O, W. W. N.; Hou, Z. J. Am. Chem. Soc. 2014, 136, 12209 – 12212. 
[12]  (a) Razavi, H.; Palaninathan, S. K.; Powers, E. T.; Wiseman, R. L.; Purkey, H. E.; Mohamedmohaideen, N. N.; 
Deechongkit, S.; Chiang, K. P.; Dendle, M. T. A.;  Sacchettini, J. C.; Kelly, J. W. Angew. Chem. Int. Ed. 2003, 
42, 2758 – 2761.  
 (b) Plemper, R. K.; Erlandson, K. J.; Lakdawala, A. S.; Sun, A.; Prussia, A.; Boonsombat, J.; Aki-Sener, E.; 
Yalcin, I.; Yildiz, I.; Temiz-Arpaci, O.; Tekiner, B.; Liotta, D. C.; Snyder, J. P.; Compans, R. W. Proc. Natl. 
Acad. Sci. U.S.A. 2004, 101, 5628 – 5633.  
 (c) McKee, M. L. Ph.D. Dissertation, University of Texas at Austin, Austin, 2007.  
 (d) McKee, M. L.; Kerwin, S. M. Bioorg. Med. Chem. 2008, 16, 1775 – 1783.  
 (e) Sommer, P. S. M.; Almeida, R. C.; Schneider, K.; Beil, W.; Süssmuth, R. D.; Fiedler, H. J. Antibiot. 2008, 
61, 683 – 686.  
 (f) Gautam, M. K.; Sonal; Sharma, N. K.; Priyanka; Jha, K. K. Int. J. ChemTech. Res. 2012, 4, 640 – 650.  
[13]  Phosphorous Ligands in Asymmetric Catalysis: Synthesis and Applications, Börner, A., Ed.; Wiley-VCH: 
Weinheim, 2008. 
[14]  Hartwig, J. Organotransition Metal Chemistry; University Science Books: Sausalito, 2010. 
[15]  (a) Reetz, M. T.; Moulin, D.; Gosberg, A. Org. Lett. 2001, 3, 4083 – 4085.  
 (b) Moss, R. J.; Wadsworth, K. J.; Chapman, C. J.; Frost, C. G. Chem. Commun. 2004, 1984 – 1985.  
 (c) Sibi, M. P.; Tatamidani, H.; Patil, K. Org. Lett. 2005, 7, 2571 – 2573.  
 (d) Frost, C. G.; Penrose, S. D.; Lambshead, K.; Raithby, P. R.; Warren, J. E.; Gleave, R. Org. Lett. 2007, 9, 
2119 – 2122.  
 (e) Navarre, L.; Martinez, R.; Genet, J.; Darses, S. J. Am. Chem. Soc. 2008, 130, 6159 – 6169. 
[16]  For established or alleged enantioselective protonation of transition metal enolates, see:  
 (a) Ref. 15b–e.  
 (b) Bergens, S. H.; Bosnich, B. J. Am. Chem. Soc. 1991, 113, 958 – 967.  
 (c) Hamashima, Y.; Somei, H.; Shimura, Y.; Tamura, T.; Sodeoka, M. Org. Lett. 2004, 6, 1861 – 1864.  
 38 
 (d) Mohr, J. T.; Hong, A. Y.; Stoltz, B. M. Nat. Chem. 2009, 1, 359 – 369.  
 (e) Hamashima, Y.; Tamura, T.; Suzuki, S.; Sodeoka, M. Synlett 2009, 1631 – 1634.  
 (f) Hamashima, Y.; Suzuki, S.; Tamura, T.; Somei, H.; Sodeoka, M. Chemistry—Asian J. 2011, 6, 658 – 668. 
[17]  Shibata, K.; Chatani, N. Org. Lett. 2014, 16, 5148 – 5151. 
[18]  [Rh(cod)OAc]2 as a hydroformylation precatalyst:  
 (a) Burke, S. D.; Cobb, J. E. Tetrahedron Lett. 1986, 27, 4237 – 4240.  
 (b) Burke, S. D.; Cobb, J. E.; Takeuchi, K. J. Org. Chem. 1990, 55, 2138 – 2151.  
 (c) da Silva, A. C.; de Oliveira, K. C. B.; Gusevskaya, E. V.; dos Santos, E. N. J. Mol. Catal. A: Chem. 2002, 
179, 133 – 141.  
 (d) Barros, H. J. V.; Ospina, M. L.; Arguello, E.; Rocha, W. R.; Gusevskaya, E. V.; dos Santos, E. N. J. 
Organomet. Chem. 2003, 671, 150 – 157.  
 (e) Barros, H. J. V.; Guimarães, C. C.; dos Santos, E. N.; Gusevskaya, E. V. Organometallics 2007, 26, 2211 –
2218. 
 (f) Barros, H. J. V.; Guimarães, C. C.; dos Santos, E. N.; Gusevskaya, E. V. Catal. Commun. 2007, 8, 747 – 
750.  
 (g) Barros, H. J. V.; da Silva, J. G.; Guimarães, C. C.; dos Santos, E. N.; Gusevskaya, E. V. Organometallics 
2008, 27, 4523 – 4531.  
 As a hydrogenation precatalyst: (h) Nagy-Magos, Z.; Vastag, S.; Heil, B.; Markó, L. J. Organomet. Chem. 
1979, 171, 97 – 102.  
 As a hydroboration precatalyst: (i) Endo, K.; Hirokami, M.; Shibata, T. Organometallics 2008, 27, 5390 – 
5393.  
 As a precatalyst for cine substitution of vinyl acetates and boronic acids:  
 (j) Yu, J.; Shimizu, R.; Kuwano, R. Angew. Chem. Int. Ed. 2010, 49, 6396 – 6399.  
 (k) Kuwano, R. J. Syn. Org. Chem. Jpn. 2011, 69, 1263 – 1270.  
[19]  Chatt, J.; Venanzi, L. M. J. Chem. Soc. 1957, 4735 – 4741. 
[20]  We deposited the crystal structure of [Rh(cod)OAc]2 to the Cambridge Crystallographic Data Centre: CCDC 
936197 
[21]  (a) van Leeuwen, P. W. N. M.; Kamer, P. C. J.; Reek, J. N. H. Pure Appl. Chem. 1999, 71, 1443 – 1452.  
 (b) van Leeuwen, P. W. N. M.; Kamer, P. C. J.; Reek, J. N. H.; Dierkes, P. Chem. Rev. 2000, 100, 2741 – 2770.  
 (c) Kamer, P. C. J.; van Leeuwen, P. W. N. M.; Reek, J. N. H. Acc. Chem. Res. 2001, 34, 895 – 904.  
 (d) Birkholz, M.; Freixab, Z.; van Leeuwen, P. W. N. M. Chem. Soc. Rev. 2009, 38, 1099 – 1118.  
 (e) Shen, Z.; Dornan, P. K.; Khan, H. A.; Woo, T. K.; Dong, V. M. J. Am. Chem. Soc. 2009, 131, 1077 – 1091.  
 39 
 (f) Ito, S.; Itoh, T.; Nakamura, M. Angew. Chem. Int. Ed. 2011, 50, 454 – 457. 
[22]  Dppe has a natural bite angle of 86° vs. 93°  
 For Binap, see: Ref. 21d.  
[23]  Segphos is known to have a smaller dihedral angle than Binap: Jeulin, S.; de Paule, S. D.; Ratovelomanana-
Vidal, V.; Genêt, J.; Champion, N.; Dellis, P. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 5799 – 5804.  
 For a demonstration of the correlation between dihedral angle and natural bite angle, see: Raebiger, J. W.; 
Miedaner, A.; Curtis, C. J.; Miller, S. M.; Anderson, O. P.; DuBois, D. L. J. Am. Chem. Soc. 2004, 126, 5502 –
5514. 
[24]  Substrate 1b (vs. 1a) was chosen for the experiment, since the C–H resonance of the azole is easily resolved 
from that of 1c.  
[25]  Chang et al. also see deuterium scrambling in the products of a reaction between ethyl acrylate and a mixture 
of proteo- and deutero-pyridine oxides (Ref. 4j). 
[26]  There could also exist irreversible steps prior to the TLS of reactive substrate 1c, but such an assumption is not 
required.    
[27]  Bocian, W.; Jaźwiński, J.; Sadlej, A. Magn. Reson. Chem. 2008, 46, 156 – 165.  
[28]  We provide no rigorous evidence that MI is turnover limiting. Yet turnover-limiting MI is consistent with the 
positive dependence of product yield on acrylate concentration (Table 2.2) as well as with the observation that 
bulky acrylates react more sluggishly than less hindered ones (Table 2.4).  
[29]  For the development of P-Phos ligands and selected examples of catalytic, asymmetric reactions that use CTH-
Xylyl-P-Phos, see:  
 (a) Ref. 5i.  
 (b) Chan, A. S. C.; Pai, C. U.S. Patent 5,886,182, 1999.  
 (c) Pai, C.; Lin, C.; Lin, C.; Chen, C.; Chan, A. S. C.; Wong, W. T. J. Am. Chem. Soc. 2000, 122, 11513 –
11514.  
 (d) Wu, J.; Chen, X.; Guo, R.; Yeung, C.; Chan, A. S. C. J. Org. Chem. 2003, 68, 2490 – 2493.  
 (e) Grasa, G. A.; Zanotti-Gerosa, A.; Medlock, J. A.; Hems, W. P. Org. Lett. 2005, 7, 1449 – 1451.  
 (f) Chan, S. H.; Lam, K. H.; Li, Y.; Xu, L.; Tang, W.; Lam, F. L.; Lo, W. H.; Yu, W. Y.; Fan, Q.; Chan, A. S. 
C. Tetrahedron: Asymmetry 2007, 18, 2625 – 2631.  
 (g) Zhang, X.; Wu. Y.; Yu, F.; Wu, F.; Wu, J.; Chan, A. S. C. Chem. Eur. J. 2009, 15, 5888 – 5891.  
[30]  In the absence of CsOAc, [Rh(cod)Cl]2 is also an ineffective precatalyst in the chemistry of Chang et al. (Ref. 
4j). 
[31]  Absolute configuration was not determined. Thus, product stereocenters are indicated with an asterisk. 
[32]  When 25 mol % CsOAc is used, [Rh(cod)Cl]2 is a competent precatalyst (see Ref. 4j). 
[33]  Hawkes, K. J.; Cavell, K. J.; Yates, B. F. Organometallics 2008, 27, 4758 – 4771. 
 40 
[34]  For a benzheterocycle-derived Rh(I)–enamido complex, see: Julius, G. R.; Cronje, S.; Neveling, A.; 
Esterhuysen, C.; Raubenheimer, H. G. Helv. Chim. Acta 2002, 85, 3737 – 3747. 
[35]  93% ee likely overestimates the degree of epimerization of 4ca under the described conditions: a minor 
impurity coelutes with the minor enantiomer, and 4ca does not epimerize in the absence of added substrates 1 
and 3 even in the presence of higher catalyst concentrations (Figure 2.11, eq. 19). 
[36]  The higher yield of 4ca obtained in the reaction with CsOAc is consistent with the accelerating effect of 
CsOAc reported earlier (see Table 2.4 and discussion). 
[37]  For reversible formation of a Rh(I)–enamido complex from an imine precursor, see: Zhao, P.; Krug, C.; 
Hartwig, J. F. J. Am. Chem. Soc. 2005, 127, 12066 – 12073. 
[38]  For simplicity, this figure shows only formation of (R)-product from O-bound XX (Figure 2.10, step 6), yet 
(S)-product is presumably also formed.  
[39]  Since the amount of deuterium in CD3CN presumably overwhelms the amount of H+ liberated from product 4, 
we approximate that one percent deuterium will incorporate into the α-position for each protonation event. 
Each (R) ! (S) conversion contributes 2% ee, which means we would need (75% starting ee - 20% final ee)/2 
~ 28 protonation events if all were selective for the minor enantiomer. In reality, protonation should give both 
enantiomers of product. A significant excess of protonation events is needed, then, to account for the observed 










A.1.1 Materials and methods ........................................................................................................................................ 42 
A.1.2 General procedure for the one-pot, one-step multicatalytic Michael–Stetter reaction (Chapter 1, eq. 1 and 
Table 1.2) ..................................................................................................................................................................... 43 
A.1.3 General procedure for the one-pot, two-step Michael–Stetter reaction of salicylaldehydes 7 and DMAD (8a) in 
the presence or absence of catechol (Chapter 1, Table 1.5) ......................................................................................... 43 
A.1.4 Procedure for the preparation of 9aa on 7.0 mmol scale ................................................................................... 43 
A.1.5 Characterization data for products 9 and 15 (Chapter 1, Table 1.2 and Table 1.6) ........................................... 44 
A.1.6 Preparation and characterization data for product 19a (Chapter 1, Table 1.7) .................................................. 48 
A.1.7 Preparation and characterization data for product 19b (Chapter 1, Table 1.7) .................................................. 48 
A.1.8 General procedure for the preparation of conjugate adducts 12aa, 12ca and 12fa with 1,4-
diazabicyclo[2.2.2]octane (DABCO, 10) or quinuclidine (11) (Chapter 1, Table 1.3–1.4 and eq. 7) ......................... 49 
A.1.9 Characterization data for conjugate adducts 12ca and 12fa ............................................................................... 49 
A.1.10 Preparation of Z-enriched 12aa (Chapter 1, eq. 8) ........................................................................................... 50 
A.1.11 Preparation of E-enriched 12aa (Chapter 1, Table 1.3–1.4 and eq. 7) ............................................................. 50 
A.1.12 General procedure for the asymmetric Stetter reaction of conjugate adducts 12 (i.e. 12 ! 9) (Chapter 1, 
Table 1.3 and eq. 9) ...................................................................................................................................................... 50 
A.1.13 Preparation and characterization of ketoalkynoates 8b–d (Chapter 1, Table 1.6) ........................................... 51 
A.1.14 1H and 13C NMR spectra for compounds 9 and 15 .......................................................................................... 54 
  
_____________________________________________________________________________________ 
[1] This appendix has been adapted with permission from supporting information for Filloux, C. M.; Lathrop, S. P.; Rovis, T. 
Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 20666 – 20671. Can be found online at: 
http://www.pnas.org/content/107/48/20666.full?tab=ds.  
 42 
A.1.1 Materials and methods 
Unless noted, all reactions were performed in flame-dried glassware and carried out under an atmosphere of 
argon with magnetic stirring. HPLC grade chloroform preserved with pentane was purchased from Fisher Scientific. 
Tetrahydrofuran (THF), diethyl ether (Et2O), and dichloromethane (DCM) were degassed with argon and passed 
through two columns of neutral alumina. Toluene was degassed with argon and passed through one column of 
neutral alumina and one column of Q5 reagent. Column chromatography was performed on SiliCycle® 
SilicaFlash® P60, 40 – 63 µm 60 Å and in general were performed according to the guidelines reported by Still et 
al.[2] Thin-layer chromatography was performed on SiliCycle® 250 µm 60 Å plates. Visualization was accomplished 
with UV light or KMnO4 stain followed by heating. 
1H NMR spectra were recorded on Varian 300 or 400 MHz spectrometers at ambient temperature unless 
otherwise stated. Data are reported as follows: chemical shift in parts per million (δ, ppm) from CDCl3 (7.26 ppm), 
toluene-d8 (7.09, 7.0, 6.98, 2.09 ppm), or benzene-d6 (7.16 ppm) multiplicity (s, singlet; bs, broad singlet; d, 
doublet; t, triplet; q, quartet; and m, multiplet), coupling constants (Hz). 13C NMR was recorded on Varian 300 or 
400 MHz spectrometers (at 75 or 100 MHz) at ambient temperature. Chemical shifts are reported in ppm from 
CDCl3 (77.2 ppm) or toluene-d8 (137.86 (1), 129.4 (3), 128.33 (3), 125.49 (3), 20.4 (5) ppm). High-resolution mass 
spectra (electrospray ionization (ESI)) were obtained by Donald Dick of Colorado State University. 
Salicylaldehydes 7a–c, 7e, and 7g–j, dimethyl acetylenedicarboxylate (DMAD) (8a), and catechol 14a were 
purchased from Aldrich or Acros and used without subsequent purification. Salicylaldehydes 7d[3] and 7f,[4] 
phosphonate ester 8e,[5] allenes 19a,[6] and 19b,[7] and triazolium precatalysts[8] 4b and ent-4b were prepared 
according to literature procedures. 
  
_____________________________________________________________________________________ 
[2]   Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923 – 2925.  
[3] Knight, P. D.; O’Shaughnessy, P. N.; Munslow, I. J.; Kimberley, B. S.; Scott, P. J. Organomet. Chem. 2003, 683, 103 – 
113.  
[4]   Toumi, M.; Couty, F.; Evano, G. Angew. Chem. Int. Ed. 2007, 46, 572 – 575.  
[5]  (a) Hall, R. G.; Trippett, S. Tetrahedron Lett. 1982, 23, 2603 – 2604.  
  (b) Myers, A. G.; Alauddin, M. M.; Fuhry, M. M.; Dragovich, P. S.; Finney, N. S.; Harrington, P. M. Tetrahedron Lett. 
1989, 30, 6997 – 7000. 
[6]  Buono, G. Synthesis 1981, 872 – 872.  
[7]  Lang, R. W.; Hansen, H. J. Helv. Chim. Acta 1980, 63, 438 – 455.  
[8]  Kerr, M. S.; Read de Alaniz, J.; Rovis, T. J. Org. Chem. 2005, 70, 5725 – 5728.  
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A.1.2 General procedure for the one-pot, one-step multicatalytic Michael–Stetter reaction (Chapter 1, eq. 1 and 
Table 1.2) 
A 1-dram vial was equipped with a magnetic stir bar under argon and charged sequentially with DMAD (8a) or 
activated alkyne 8b–d (0.15 mmol), salicylaldehyde 7 (0.16 mmol), and triazolium salt 4b (14 mg, 0.030 mmol). 
Toluene (1.5 mL) was added, and the mixture was cooled to 0 °C. Quinuclidine (11) (3.0 mg, 0.030 mmol) or 1,4-
diazabicyclo[2.2.2]octane (DABCO) (10) (3.0 mg, 0.030 mmol) was added in one portion, and the reaction was 
monitored by TLC (Hex:Acetone). Note: many benzofuranone products 9 coelute with intermediate conjugate 
adducts 12 in Hex:EtOAc solvent systems. Resolution was typically accomplished with a Hex:Acetone system. When 
the reaction was observed to be complete, the mixture was quenched with glacial acetic acid (1–2 drops), filtered 
through a plug of silica with Et2O (~ 40 mL), and concentrated in vacuo. The resulting crude product 9 was purified 
via flash column chromatography on silica gel. 
A.1.3 General procedure for the one-pot, two-step Michael–Stetter reaction of salicylaldehydes 7 and DMAD (8a) 
in the presence or absence of catechol (Chapter 1, Table 1.5) 
A 1-dram vial was equipped with a magnetic stir bar under argon and charged with DMAD (8a) (21 mg, 0.15 
mmol) and salicylaldehdyde 7 (0.16 mmol). Toluene (1.5 mL) was added, and the mixture was cooled to 0 °C. 
Quinuclidine (11) (3.0 mg, 0.030 mmol) or DABCO (10) (3.0 mg, 0.030 mmol) was added in one portion, and the 
reaction was monitored by TLC (EtOAc:Hex) until consumption of 8a was observed to be complete. Catechol (if 
used) (0.015 mmol) was added to the reaction followed by triazolium salt precatalyst 4b (14 mg, 0.030 mmol). The 
reaction was again monitored by TLC (Hex:Acetone) until conversion of intermediate aldehyde 12 to product 9 was 
complete. At this time, the reaction mixture was quenched with glacial acetic acid (1–2 drops), filtered through a 
plug of silica with Et2O (~ 40 mL), and concentrated in vacuo. The resulting crude product 9 was purified by flash 
column chromatography on silica gel. 
A.1.4 Procedure for the preparation of 9aa on 7.0 mmol scale 
A 250 mL, flame-dried, round-bottom flask was charged with triazolium salt 4b (164 mg, 0.350 mmol) and 
evacuated for 3 min, then filled with argon. After the evacuation procedure was repeated an additional two times, 
DMAD (8a) (1.01 g, 7.12 mmol), salicylaldehyde (7a) (933 mg, 7.64 mg), and toluene (72 mL) were added 
sequentially, and the reaction mixture was cooled to 0 °C. Quinuclidine (11) (156 mg, 1.40 mmol) was added 
portionwise to the reaction mixture. After stirring at 0 °C for 9 h, the reaction was quenched with glacial acetic acid 
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(150 µL) and poured directly onto a silica gel column (5∶1!1∶1 Hex:EtOAc) to give 1.48 g (79% yield) 9aa as a 
clear, amorphous solid. 
A.1.5 Characterization data for products 9 and 15 (Chapter 1, Table 1.2 and Table 1.6) 
9aa. Rf = 0.24 (3:1 Hex:EtOAc); [α]D25 = +99.1° (c = 1.56 g/100 mL, CHCl3); HPLC analysis – 
Chiracel IC column, 60:40 Hex:iPrOH, 0.7 mL/min, major enantiomer: 14.9 min, minor 
enantiomer: 27.0 min, 89% ee; 1H NMR (400 MHz, CDCl3) δ 7.66 (m, 2H), 7.22 (d, 1H, J = 8.4 Hz), 7.14 (t, 1H, J 
= 7.5 Hz), 3.76 (s, 3H), 3.64 (s, 3H), 3.47 (d, 1H, J = 17.5 Hz), 3.10 (d, 1H, J = 17.5); 13C NMR (100 MHz, CDCl3) 
δ 194.6, 172.3, 169.0, 165.6, 138.7, 125.1, 123.1, 119.5, 113.7, 88.0, 53.8, 52.4, 38.5; IR (Thin Film/NaCl) 2950, 
1747, 1727, 1614, 1465, 1214 cm-1; HRMS (ESI) m/z [C13H13O6]+ calcd ([M+H]+) 265.0707, found 265.0710.  
9ba. Rf = 0.26 (3:1 Hex:EtOAc); [α]D25 = +56.6° (c = 1.46 g/100 mL, CHCl3); HPLC 
analysis – Chiracel IC column, 50:50 Hex:iPrOH, 0.7 mL/min, major enantiomer: 13.7 min, 
minor enantiomer: 20.7 min, 89% ee; 1H NMR (400 MHz, CDCl3) δ 7.65 (d, 1H, J = 2.3 Hz), 7.60 (dd, 1H, J = 8.8, 
2.3 Hz), 7.17 (d, 1H, J = 8.8 Hz), 3.77 (s, 3H), 3.65 (s, 3H), 3.45 (d, 1H, J = 17.6 Hz), 3.21 (d, 1H, J = 17.6); 13C 
NMR (100 MHz, CDCl3) δ 193.6, 170.7, 168.8, 165.2, 138.4, 128.7, 124.4, 121.0, 115.0, 88.9, 53.9, 52.5, 38.4; IR 
(Thin Film/NaCl) 2956, 1756, 1735, 1606, 1463, 1212 cm-1; HRMS (ESI) m/z  [C13H11ClNaO6]+ ([M+H]+) calcd 
321.0136, found 321.0137. 
9ca. Rf = 0.25 (7:2 Hex:EtOAc); [α]D25 = +56.7° (c = 1.60 g/100 mL, CHCl3); HPLC 
analysis – Chiracel IC column, 50:50 Hex:iPrOH, 0.7 mL/min, major enantiomer: 14.2 min, 
minor enantiomer: 20.5 min, 94% ee; 1H NMR (400 MHz, CDCl3) δ 7.79 (d, 1H, J = 1.6 Hz), 7.72 (dd, 1H, J = 8.8, 
1.6 Hz), 7.12 (d, 1H, J = 8.8 Hz), 3.75 (s, 3H), 3.63 (s, 3H), 3.43 (d, 1H, J = 17.6 Hz), 3.20 (d, 1H, J = 17.6); 13C 
NMR (100 MHz, CDCl3) δ 193.4, 171.0, 168.8, 165.2, 141.1, 127.5, 121.5, 115.6, 115.3, 88.7, 53.9, 52.5, 38.4; IR 
(Thin Film/NaCl) 2950, 1757, 1737, 1609, 1460, 1440, 1214 cm-1; HRMS (ESI) m/z [C13H11BrNaO6]+ ([M+H]+) 
calcd 364.9631, found 364.9637. 
9da. Rf = 0.28 (3:1 Hex:EtOAc); [α]D25 = +54.6° (c = 2.19 g/100 mL, CHCl3); HPLC analysis 
– Chiracel IC column, 60:40 Hex:iPrOH, 0.7 mL/min, major enantiomer: 16.5 min, minor 
enantiomer: 22.4 min, 94% ee; 1H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H), 7.88 (d, 1H, J = 8.7 Hz) 7.02 (d, 1H, J = 





















193.1, 171.7, 168.8, 165.1, 146.6, 133.6, 122.1, 115.8, 88.3, 85.3, 53.9, 52.4, 38.4; IR (Thin Film/NaCl) 2955, 1756, 
1737, 1603, 1455, 1434, 1209 cm-1; HRMS (ESI) m/z [C13H11INaO6]+ ([M+H]+) calcd 412.9493, found 412.9497. 
9ea. Rf  = 0.23 (3:1 Hex:EtOAc); [α]D25 = +78.0° (c = 1.60 g/100 mL, CHCl3); HPLC 
analysis – Chiracel IC column, 60:40 Hex:iPrOH, 0.7 mL/min, major enantiomer: 15.6 min, 
minor enantiomer: 19.7 min, 86% ee; 1H NMR (400 MHz, CDCl3) δ 7.47 (m, 2H), 7.12 (m, 1H), 3.76 (s, 3H), 3.65 
(s, 3H), 3.46 (d, 1H, J = 17.4 Hz), 3.09 (d, 1H, J = 17.4 Hz), 2.35 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 194.7, 
170.9, 169.0, 165.8, 140.0, 132.8, 124.5, 119.4, 113.3, 88.3, 53.7, 52.4, 38.6, 20.7; IR (Thin Film/NaCl) 2953, 1747, 
1721, 1619, 1490, 1440, 1209 cm-1; HRMS (ESI) m/z [C13H15O6]+ ([M+H]+) calcd 279.0863, found 279.0865. 
9fa. Rf = 0.26 (4:1 Hex:EtOAc); [α]D25 = +87.3° (c = 1.95 g/100 mL, CHCl3); HPLC 
analysis – Chiracel IC column, 90:10 Hex:iPrOH, 0.7 mL/min, major enantiomer: 20.8 
min, minor enantiomer: 16.4 min, 85% ee; 1H NMR (400 MHz, CDCl3) δ 7.73 (dd, 1H, J = 8.8, 2.0 Hz), 7.65 (d, 1H, 
J =1.7 Hz), 7.16 (d, 1H, J = 8.8 Hz), 3.76 (s, 3H), 3.66 (s, 3H), 3.48 (d, 1H, J = 17.4 Hz), 3.04 (d, 1H, J = 17.4 Hz), 
1.31 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 194.8, 170.8, 169.1, 165.8, 146.4, 137.0, 121.0, 118.8, 113.1, 88.5, 53.7, 
52.4, 38.6, 34.7, 31.4; IR (Thin Film/NaCl) 2960, 2905, 1747, 1726, 1619, 1491, 1210 cm-1; HRMS (ESI) m/z 
[C17H21O6]+ ([M+H]+) calcd 321.1333, found 321.1337. 
9ga. Rf = 0.26 (2:1 Hex:EtOAc); [α]D25 = +73.6° (c = 1.48 g/100 mL, CHCl3); HPLC 
analysis – Chiracel IC column, 50:50 Hex:iPrOH, 0.7 mL/min, major enantiomer: 19.9 
min, minor enantiomer: 14.5 min, 86% ee; 1H NMR (400 MHz, CDCl3) δ 7.29 (dd, 1H, J = 9.0, 2.8 Hz), 7.16 (d, 1H, 
J = 9.0 Hz), 7.07 (d, 1H, J = 2.8 Hz), 3.81 (s, 3H), 3.78 (s, 3H), 3.67 (s, 3H) 3.47 (d, 1H, J = 17.4 Hz), 3.11 (d, 1H, J 
= 17.4); 13C NMR (100 MHz, CDCl3) δ 194.8, 169.0, 167.8, 165.8, 155.8, 128.7, 119.5, 114.6, 104.8, 88.8, 56.0, 
53.8, 52.4, 38.6; IR (Thin Film/NaCl) 2955, 1747, 1716, 1491, 1440, 1209 cm-1; HRMS (ESI) m/z [C14H15O7]+ 
([M+H]+) calcd 295.0812, found 295.0809. 
9ha. Rf = 0.22 (2:1 Hex:EtOAc); [α]D25 = +171.3° (c = 1.71 g/100 mL, CHCl3); HPLC 
analysis – Chiracel IC column, 50:50 Hex:iPrOH, 1.0 mL/min, major enantiomer: 40.7 
min, minor enantiomer: 24.5 min, 85% ee; 1H NMR (400 MHz, CDCl3) δ  7.56 (d, 1H, J = 8.6 Hz), 6.68 (m, 2H), 
3.88 (s, 3H), 3.77 (s, 3H), 3.67 (s, 3H), 3.48 (d, 1H, J = 17.4 Hz), 3.00 (d, 1H, J = 17.4 Hz); 13C NMR (100 MHz, 






















Film/NaCl) 2950, 1747, 1711, 1614, 1440, 1286 cm-1; HRMS (ESI) m/z [C14H15O7]+ ([M+H]+) calcd 295.0812, 
found 295.0812. 
9ia. Rf = 0.29 (3:2 Hex:EtOAc); [α]D25 = +70.1° (c = 0.850 g/100 mL, CHCl3); HPLC analysis 
– Chiracel IC column, 60:40 Hex:iPrOH, 0.7 mL/min, major enantiomer: 19.9 min, minor 
enantiomer: 33.5 min, 92% ee; 1H NMR (400 MHz, CDCl3) δ  7.28 (dd, 1H, J =7.7, 1.2  Hz), 
7.16 (dd, 1H, J = 7.9, 1.1 Hz), 7.09 (t, 1H, J = 7.8 Hz), 3.96 (s, 3H), 3.75 (s, 3H), 3.63 (s, 3H), 3.46 (d, 1H, J = 17.6 
Hz), 3.30 (d, 1H, J = 17.6 Hz); 13C NMR (100 MHz, CDCl3) δ 195.0, 168.8, 165.6, 162.4, 146.5, 123.6, 121.1, 
119.3, 116.0, 88.3, 56.4, 53.9, 52.4, 38.4; IR (ATR) 2956, 1723, 1617, 1504, 1438, 1206 cm-1; HRMS (ESI) m/z 
[C14H14NaO7]+ ([M+Na]+) calcd 317.0632, found 317.0637. 
9ab. Rf = 0.30 (3:1 Hex:EtOAc); [α]D25 = +15.4° (c = 1.05 g/100 mL, CHCl3); HPLC analysis – 
Chiracel IC column, 90:10 Hex:iPrOH, 0.7 mL/min, major enantiomer: 21.8 min, minor 
enantiomer: 18.6 min, 12% ee; 1H NMR (400 MHz, CDCl3) δ 7.93 (m, 2H), 7.65 (m, 3H), 7.46 
(m, 2H), 7.19 (m, 2H), 4.24 (m, 3H), 3.69 (d, 1H, J = 18.2 Hz), 1.24 (t, 3H, J = 7.1 Hz); 13C NMR (100 MHz, 
CDCl3) δ 195.7, 194.2, 172.5, 165.6, 138.6, 135.9, 133.9, 128.9, 128.3, 125.0, 122.9, 119.7, 113.8, 88.4, 63.0, 43.4, 
14.1; IR (Thin Film/NaCl) 2978, 1747, 1726, 1690, 1614, 1460, 1224 cm-1; HRMS (ESI) m/z [C19H17O5]+ ([M+H]+)  
calcd 325.1071, found 325.1078. 
9ac. Rf = 0.26 (2:1 Hex:EtOAc); [α]D25 = +24.2° (c = 1.36 g/100 mL, CHCl3); HPLC 
analysis – Chiracel IC column, 85:15 Hex:iPrOH, 0.7 mL/min, major enantiomer: 38.3 
min, minor enantiomer: 42.5 min, 18% ee; 1H NMR (400 MHz, CDCl3) δ 7.91 (d, 2H, J 
= 8.9 Hz), 7.73 (d, 1H, J = 7.7 Hz), 7.66 (m, 1H), 7.23 (d, 1H, J = 8.4 Hz), 7.16 (t, 1H, J = 7.5 Hz), 6.92 (d, 2H, J = 
8.9 Hz), 4.19 (d, 1H, J = 18.1 Hz), 3.86 (s, 3H), 3.79 (s, 3H), 3.67 (d, 1H, J = 18.1 Hz); 13C NMR (100 MHz, 
CDCl3) δ 195.6, 192.6, 172.3, 166.3, 164.1, 138.6, 130.7, 128.9,125.0, 122.9, 119.7, 114.0, 113.8, 88.5, 55.6, 53.7, 
43.2; IR (Thin Film/NaCl) 2955, 1753, 1722, 1679, 1600, 1462, 1264, 1233 cm-1; HRMS (ESI) m/z [C19H16NaO6]+ 
([M+Na]+) calcd 363.0839, found 363.0845. 
9ad. Rf = 0.21 (2:1 pentane:Et2O); [α]D25 = +35.9° (c = 0.370 g/100 mL, CHCl3); HPLC 
analysis – Chiracel IC column, 90:10 Hex:iPrOH, 0.7 mL/min, major enantiomer: 47.0 min, 



















7H), 4.22 (dq, 1H, J = 10.8, 7.1 Hz), 4.19 (dq, 1H, J = 10.8, 7.1 Hz), 3.61 (d, 1H, J = 18.2 Hz), 3.13 (d, 1H, J = 18.2 
Hz), 2.78 (m, 2H), 2.75 (m, 2H), 1.22 (t, 3H, J = 7.1 Hz); 13C NMR (100 MHz, CDCl3) δ 204.0, 195.3, 172.4, 165.4, 
140.6, 138.6, 128.7, 128.4, 126.4, 125.0, 122.9, 119.6, 113.7, 88.2, 63.0, 46.7, 44.3, 29.5, 14.0; IR (Thin Film/NaCl) 
2981, 1751, 1722, 1612, 1462, 1247   cm -1; HRMS (ESI) m/z [C21H20NaO5]+ ([M+Na]+) calcd 375.1203, found 
375.1199. 
9ae. A 1-dram vial equipped with a magnetic stir bar under argon was charged with 
phosphonate 8e (51 mg, 0.22 mmol), salicylaldehdyde (7a) (28 mg, 0.23 mmol), and toluene 
(2.2 mL). Quinuclidine (11) (5.0 mg, 0.040 mmol) was added in one portion, and the reaction 
mixture was stirred for 25 h at 23 °C. At this point, the reaction mixture was cooled to 0 °C, and triazolium salt 4b 
(20 mg, 0.040 mmol) was added. After an additional 75 minutes of stirring, the mixture was quenched with glacial 
acetic acid (2 drops), filtered through a plug of silica with Et2O (~ 40 mL), and concentrated in vacuo. Flash column 
chromatography on silica gel yielded 28 mg (36% yield) of partially purified 9ae, which was contaminated with 
about 20% chromene impurity which coeluted in a variety of solvent systems. Rf = 0.35 (95:5 DCM:MeOH); [α]D25 
= +32.4° (c = 0.230 g/100 mL, CHCl3); HPLC analysis – Chiracel ASH column, 85:15 Hex:iPrOH, 1.0 mL/min, 
major enantiomer: 10.0 min, minor enantiomer: 8.2 min, 86% ee; 1H NMR (400 MHz, CDCl3) δ 7.67 (m, 2H), 7.26 
(m, 1H), 7.15, (m, 1H), 4.23 (q, 2H, J = 7.1 Hz), 4.00–4.07 (m, 4H), 2.98 (dd, 1H, J = 16.9, 15.9 Hz), 2.62 (dd, 1H, 
J = 18.1, 15.8 Hz), 1.23 (m, 9H) ; 13C NMR (100 MHz, CDCl3) δ 195.1 (d, J = 7.3 Hz), 172.3, 165.4 (d, J = 12.8 
Hz), 138.7, 125.2, 123.0, 119.4, 113.7, 87.4 (d, J = 7.4 Hz), 63.2, 62.3 (d, J = 5.6 Hz), 62.1 (d, J = 6.8 Hz), 30.7 (d, J 
= 145.0 Hz), 16.4 (d, J = 6.9 Hz), 14.1; 31P NMR (121 MHz, CDCl3) δ 24.0 (s); IR (Thin Film/NaCl) 2984, 2930, 
1753, 1729, 1613, 1463, 1247, 1026 cm-1; HRMS (ESI) m/z [C16H22O7P]+ ([M+H]+) calcd 357.1098, found 357.1099. 
15ad. Rf = 0.29 (2:1 pentane:Et2O); HPLC analysis – Chiracel IC column, 90:10 Hex:iPrOH, 
0.7 mL/min, major enantiomer: 19.2 min, minor enantiomer: 60.5 min, 89% ee; 1H NMR 
(400 MHz, CDCl3) δ 7.68 (m, 2H), 7.08–7.26 (m, 7H), 4.09 (q, 2H, J = 7.2 Hz), 3.52 (d, 1H, 
J = 17.2 Hz), 3.21 (ddd, 1H, J = 18.5, 9.9, 5.6 Hz), 2.96 (d, 1H, J = 17.2 Hz), 2.89 (ddd, 1H, J = 14.6, 9.6, 5.4 Hz), 
2.80 (ddd, 1H, J = 14.6, 10.0, 5.3 Hz), 2.52 (ddd, 1H, J = 18.5, 9.8, 5.6 Hz), 1.16 (t, 3H, J = 7.2 Hz); IR (Thin 













15ae. 1H NMR (400 MHz, CDCl3) δ 7.73 (m, 1H), 7.61 (m, 1H), 7.16, (m, 2H), 4.21 (m, 4H), 
3.94 (m, 2H), 3.51 (dd, 1H, J = 17.1, 3.1 Hz), 3.34 (dd, 1H, J = 17.1, 9.2 Hz), 1.32 (t, 3H, J = 7.1 
Hz), 1.22 (t, 3H, J = 7.1 Hz), 0.96 (t, 3H, J = 7.2 Hz). 
A.1.6 Preparation and characterization data for product 19a (Chapter 1, Table 1.7)  
19a. A 1-dram vial was equipped with a magnetic stir bar under argon and charged with allenone 
18a (27 mg, 0.33 mmol), salicylaldehdyde (7a) (37 mg, 0.30 mmol), and THF (1.5 mL). 
Quinuclidine (11) (6.7 mg, 0.060 mmol) was added in one portion, and the reaction mixture was 
stirred at 23 °C until consumption of 7a was observed to be complete by TLC (Hex:EtOAc). At this point, the 
reaction mixture was cooled to 0 °C, triazolium salt 4b (28 mg, 0.060 mmol) was added, and the reaction was again 
monitored by TLC (Hex:Acetone). When the reaction was observed to be complete, the mixture was quenched with 
glacial acetic acid (2 drops), filtered through a plug of silica with Et2O (~ 40 mL), and concentrated in vacuo. Flash 
column chromatography on silica gel yielded 37 mg (60% yield) of 19a. Rf = 0.22 (3∶1 Hex:EtOAc); [α]D25 = -5.6° 
(c = 1.84 g/100 mL, CHCl3); HPLC analysis – Chiracel ADH column, 97:3  Hex:iPrOH, 1.0 mL/min, major 
enantiomer: 14.4 min, minor enantiomer: 16.5 min, 78% ee; 1H NMR (400 MHz, CDCl3) δ  7.70 (ddd, 1H, J = 7.7, 
1.4, 0.6 Hz), 7.59 (ddd, 1H, J = 8.5, 7.3, 1.5 Hz), 7.07 (m, 2H), 3.15 (d, 1H, J = 17.3 Hz), 3.09 (d, 1H, J = 17.2 Hz), 
2.11 (s, 3H), 1.42 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 203.4, 203.1, 170.8, 137.7, 124.7, 122.0, 120.8, 113.3, 
86.4, 50.1, 30.4, 22.5; IR (Thin Film/NaCl) 2359, 1712, 1610, 1462, 1367 cm-1; HRMS (ESI) m/z [C12H13O3]+ 
([M+H]+) calcd 205.0859, found 205.0863. 
A.1.7 Preparation and characterization data for product 19b (Chapter 1, Table 1.7) 
19b. A 1-dram vial was equipped with a magnetic stir bar under argon and charged with 
allenoate 18b (47 mg, 0.42 mmol), salicylaldehdyde (7a) (46 mg, 0.38 mmol) and solvent (1.5 
mL). Quinuclidine (11) (8.4 mg, 0.076 mmol) was added in one portion, and the reaction 
mixture was stirred at 23 °C until consumption of 7a was observed to be complete by TLC (DCM:EtOAc). At this 
point, triazolium salt 4b (35 mg, 0.076 mmol) was added, and the reaction was again monitored by TLC 
(Hex:Acetone). When the reaction was observed to be complete, the mixture was quenched with glacial acetic acid 
(2 drops), filtered through a plug of silica with Et2O (~ 40 mL), and concentrated in vacuo. Flash column 
chromatography on silica gel yielded 52 mg (59% yield) of 19b. Rf = 0.27 (4:1 Hex:EtOAc); [α]D25 = -11.3° (c = 

















44.0 min, minor enantiomer: 25.9 min, 96% ee; 1H NMR (400 MHz, CDCl3) δ  7.70 (m, 1H), 7.60 (m, 1H), 7.09 (m, 
2H), 3.99 (dq, 1H, J = 10.8, 7.1 Hz), 3.93 (dq, 1H, J = 10.8, 7.1 Hz), 3.05 (d, 1H, J = 16.3 Hz), 2.92 (d, 1H, J = 16.3 
Hz), 1.46 (s, 3H), 0.98 (t, 3H, J = 7.1 Hz); 13C NMR (100 MHz, CDCl3) δ 202.8, 171.1, 168.6, 137.9, 124.7, 122.0, 
120.7, 113.4, 86.5, 61.0, 41.8, 22.7, 13.8; IR (Thin Film/NaCl) 2980, 1721, 1612, 1464, 1213 cm-1; HRMS (ESI) m/z 
[C13H15O4]+ ([M+H]+) calcd 235.0965, found 235.0967. 
A.1.8 General procedure for the preparation of conjugate adducts 12aa, 12ca and 12fa with DABCO (10) or 
quinuclidine (11) (Chapter 1, Table 1.3–1.4 and eq. 7) 
A flame-dried, 50 mL round-bottom flask was charged with DMAD (8a) (2.0 mmol), salicylaldehdyde (7a) (2.1 
mmol), and toluene (20 mL) under argon. The mixture was cooled to 0 °C, and quinuclidine (11) or DABCO (10) 
(0.40 mmol) was added in one portion. After stirring for 30 – 60 min, the reaction mixture was concentrated in 
vacuo, and the resulting crude product 12 was purified by flash column chromatography on silica gel. 
A.1.9 Characterization data for conjugate adducts 12aa, 12ca and 12fa 
12aa. Characterization data for 12aa matched that reported in the literature.[9] 12aa was isolated 
as a > 20:1 mixture of E:Z isomers (E = 5a in Ref. 8; Z = 4a in Ref. 8). The vinylic resonance of 
E-12aa appears at 5.40 ppm, and the vinylic resonance of Z-12aa appears at 6.87 ppm. 
12ca. 12ca was obtained as a 16:1 E:Z mixture. 1H and 13C data is for E isomer only. Rf = 
0.24 (3:1 Hex:EtOAc); 1H NMR (400 MHz, CDCl3) δ 10.21 (s, 1H), 8.06 (d, 1H, J =2.5 Hz), 
7.75 (dd, 1H, J = 8.7, 2.5 Hz), 7.10 (d, 1H, J = 8.7 Hz), 5.32 (s, 1H), 3.91 (s, 3H), 3.71 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 186.4, 165.0, 162.3, 158.8, 154.3, 138.8, 132.1, 129.1, 123.3, 120.3, 103.4, 53.5, 52.2; IR (ATR) 
2953,1747, 1712, 1687, 1645, 1627, 1360, 1126 cm-1; HRMS (ESI) m/z [C13H11BrNaO6]+ ([M+Na]+) calcd 364.9631, 
found 364.9631.  
12fa. 12fa was obtained as a > 20:1 E:Z mixture. 1H and 13C data is for E isomer only. Rf = 
0.24 (4:1 Hex:EtOAc); 1H NMR (400 MHz, CDCl3) δ 10.25 (s, 1H), 7.96 (d, 1H, J =2.6 
Hz), 7.68 (dd, 1H, J = 8.6, 2.6 Hz), 7.12 (d, 1H, J = 8.6 Hz), 5.18 (s, 1H), 3.93 (s, 3H), 3.68 (s, 3H), 1.34 (s, 9H); 
13C NMR (100 MHz, CDCl3) δ 188.1, 165.4, 162.8, 160.7, 153.0, 150.5, 133.4, 127.2, 125.9, 121.5, 100.9, 53.4, 
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52.1, 35.0, 31.3; IR (Thin Film/NaCl) 2958, 2870, 1754, 1726, 1695, 1639, 1365, 1133 cm-1; HRMS (ESI) m/z 
[C17H21NaO6]+ ([M+Na]+) calcd 343.1152, found 343.1153. 
A.1.10 Preparation of Z-enriched 12aa (Chapter 1, eq. 8) 
Z-enriched 12aa was prepared according to the method of Gupta and George:[9] A mixture of salicylaldehyde 
(7ab) (702 mg, 5.8 mmol, 1.0 equiv), DMAD (8a) (817 mg, 5.8 mmol, 1.0 equiv) and K2CO3 (802 mg, 5.8 mmol, 
1.0 equiv) in benzene (7.2 mL) was heated to relux under argon. An additional 802 mg (1.0 equiv) K2CO3 was 
added 2h later, and the reaction was heated at reflux again until it was deemed complete by TLC (9:4 Hex:EtOAc). 
At this point, the brown reaction mixture was cooled to room temperature and purified by flash column 
chromatography on silica gel (9:4 Hex:EtOAc). Purest fractions were combined to give 12aa (108 mg, 7%) as a ~ 
6.9:1 (Z:E) mixture of stereoisomers (Figure A.1.1). 
A.1.11 Preparation of E-enriched 12aa (Chapter 1, Table 1.3–1.4 and eq. 7) 
E-enriched 12aa (Figure A.1.1) was prepared according to the general procedure (A.1.8). 
 
Figure A.1.1 1H NMR spectra for Z-enriched 12aa (top) and E-enriched 12aa (bottom). The vinylic resonance of E-
12aa appears at 5.40 ppm, and the vinylic resonance of Z-12aa appears at 6.87 ppm. 
A.1.12 General procedure for the asymmetric Stetter reaction of conjugate adducts 12 (i.e. 12 !  9) (Chapter 1, 
Table 1.3 and eq. 9) 
To a solution of 12aa (34.6 mg, 0.31 mmol, 1.0 equiv) in toluene (1.3 mL) was added triazolium salt 4b (12.4 
mg, 0.20 equiv), and the reaction mixture was cooled to 0 °C. Quinuclidine (11) (2.7 mg, 0.20 equiv) or DABCO 
(10) (2.9 mg, 0.20 equiv) was added at this time, and the reaction was stirred at 0 °C under it was observed to be 
complete by TLC (Hex:Acetone). The reaction mixture was quenched with glacial acetic acid (1–2 drops), filtered 
 51 
through a plug of silica with Et2O (~ 40 mL), and concentrated in vacuo. The resulting crude product 9 was purified 
by flash column chromatography on silica gel. 
A.1.13 Preparation and characterization of ketoalkynoates 8b–d (Chapter 1, Table 1.6) 
Ketoalkynoates were oxidized from the corresponding propargylic alcohols, which were prepared according to a 
modified literature procedure (eq. 1):[10] 
 
8b. To a solution of LiHMDS (2.53 g, 15.1 mmol, 1.2 equiv) in THF (30 mL) at -78°C was added 
ethyl propiolate (1.36 g, 13.9 mmol, 1.1 equiv) in THF (13 mL) over 30 minutes via syringe pump. 
The resultant mixture was stirred for 30 minutes, at which point a solution of benzaldehyde (1.34 g, 12.6 mmol, 1.0 
equiv) in THF (6.0 mL) was added via syringe pump over 30 minutes. After an additional 45 minutes of stirring, the 
reaction mixture was quenched with saturated NH4Cl and allowed to warm to room temperature. The organic layer 
was diluted with Et2O, washed with NH4Cl, H2O and brine and dried over MgSO4. Concentration and flash column 
chromatography on silica gel gave 1.77 g (69% yield) of crude propargylic alcohol.  
To a solution of the crude alcohol (494 mg, 2.42 mmol) in DCM (2.4 mL) at 0 °C was added dropwise a 
solution of MnO2 (1.48 g, 17.0 mmol) in DCM (1.2 mL). The ice bath was removed, and the reaction mixture was 
allowed to stir at 23 °C for 4 h. Filtration through celite and purification by flash column chromatography on silica 
gel gave 260 mg of 8b (36% yield over two steps) as a light yellow oil. Rf = 0.35 (5:1 Hex:EtOAc); 1H NMR (400 
MHz, CDCl3) δ 8.12 (dd, 2H, J = 8.0, 0.4 Hz), 7.67 (t, 1H, J = 7.2 Hz), 7.52 (t, 2H, J = 8.0 Hz), 4.35 (q, 2H, J = 7.2 
Hz), 1.37 (t, 3H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 176.3, 152.4, 135.7, 135.3, 129.9, 129.0, 80.6, 79.9, 
63.2, 14.1; IR (Thin Film/NaCl) 2986, 1719, 1653, 1450, 1262 cm-1; LRMS (GC) m/z [C12H10O3] ([M]+) calcd 202, 
found 202.  
_____________________________________________________________________________________ 
[10]  Crimmins, M. T.; Nantermet, P. G.; Trotter, B. W.; Vallin, I. M.; Watson, P. S.; McKerlie, L. A.; Reinhold, T. L.; Cheung, 
























8c. To a solution of LiHMDS (836 mg, 5.00 mmol, 1.2 equiv) in THF (10 mL) at -78 °C 
was added methyl propiolate (386 mg, 4.59 mmol, 1.1 equiv) in THF (4.2 mL) over 30 
minutes via syringe pump. The resultant mixture was stirred for 30 minutes, at which point a 
solution of p-anisaldehyde (566 mg, 4.16 mmol, 1.0 equiv) in THF (2.0 mL) was added via syringe pump over 20 
minutes. After an additional 45 minutes of stirring, the reaction mixture was quenched with saturated NH4Cl and 
allowed to warm to room temperature. The organic layer was diluted with Et2O, washed with NH4Cl, H2O and brine 
and dried over MgSO4. Concentration and flash column chromatography on silica gel gave 744 mg (81% yield) of 
crude propargylic alcohol.  
To a solution of the crude alcohol (473 mg, 2.15 mmol, 1.0 equiv) in DCM (11 mL) at 0 °C was added Dess–
Martin Periodinane (DMP) (1.01 g, 2.38 mmol, 1.1 equiv) portion-wise. After stirring for 90 minutes at 0 °C and 
another 2 h at 23 °C, the reaction mixture was again cooled to 0 °C and another portion of DMP (275 mg, 0.650 
mmol) was added. The reaction was placed in the fridge (-5 °C) overnight and then quenched with a 1:1 mixture of 
Na2S2O3:NaHCO3 (12 mL). The biphasic mixture was stirred until both layers cleared, at which point the organic 
layer was diluted with Et2O, washed with H2O and brine and dried over MgSO4. Concentration and purification by 
flash column chromatography on silica gel gave 154 mg of 8c (26% yield over two steps) as a white powder. Rf = 
0.26 (7:2 Hex:EtOAc); 1H NMR (400 MHz, CDCl3) δ 8.08 (d, 2H, J = 9.0 Hz), 6.97 (d, 2H, J = 9.0 Hz), 3.90 (s, 3H), 
3.88 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 174.6, 165.5, 153.0, 132.4, 129.2, 114.4, 80.5, 79.7, 55.9, 53.5; IR 
(Thin Film/NaCl) 2959, 1712, 1638, 1596, 1254 cm-1; HRMS (ESI) m/z [C12H11O4]+ ([M+H]+) calcd 219.0652, 
found 219.0653. 
8d. To a solution of LiHMDS (2.55 g, 15.2 mmol, 1.2 equiv) in THF (30 mL) at -78°C was 
added ethyl propiolate (1.37 g, 13.9 mmol, 1.1 equiv) in THF (13 mL) over 30 minutes via 
syringe pump. The resultant mixture was stirred for 30 minutes, at which point a solution of hydrocinnamaldehyde 
(1.70 g, 12.7 mmol, 1.0 equiv) in THF (6.0 mL) was added via syringe pump over 20 minutes. After an additional 
45 minutes of stirring, the reaction mixture was quenched with saturated NH4Cl and allowed to warm to room 
temperature. The organic layer was diluted with Et2O, washed with NH4Cl, H2O and brine and dried over MgSO4. 









To a solution of the crude alcohol (465 mg, 2.00 mmol, 1.0 equiv) in DCM (10 mL) at 0 °C was added Dess–
Martin Periodinane (DMP) (938 mg, 2.21 mmol, 1.1 equiv) portion-wise. The reaction was stirred for 3 h at 23 °C 
and then placed in the fridge (-5 °C) overnight. Another portion of DMP (155 mg, 0.365 mmol) was added at this 
point, and the reaction was allowed to stir for an additional 4 h at 23 °C before it was quenched with a 1:1 mixture 
of Na2S2O3:NaHCO3 (13 mL). The biphasic mixture was stirred until both layers cleared, at which point the organic 
layer was diluted with Et2O, washed with H2O and brine and dried over MgSO4. Concentration and purification by 
flash column chromatography on silica gel gave 373 mg of 8d (50% yield over two steps) as a clear oil. Rf = 0.48 
(4:1 Hex:EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.30 (m, 2H), 7.21 (m, 3H), 4.31 (q, 2H, J = 7.2 Hz), 2.99 (m, 4H), 
1.34 (t, 3H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 184.9, 152.2, 139.6, 128.7, 128.4, 126.6, 80.5, 78.6, 63.1, 
46.8, 29.3, 14.0; IR (Thin Film/NaCl) 3029, 2985, 1721, 1689, 1496, 1244 cm-1; LRMS (GC) m/z [C14H14O3] ([M]+) 
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A.2.1 Materials and methods 
 Unless noted, all reactions were performed in flame-dried glassware and carried out under an atmosphere of 
argon with magnetic stirring. Tetrahydrofuran (THF), diethylether (Et2O), and dichloromethane (DCM) were 
degassed with argon and passed through two columns of neutral alumina. Toluene was degassed with argon and 
passed through one column of neutral alumina and one column of Q5 reagent. Anhydrous acetonitrile was purchased 
in the Sure Seal® from Aldrich Chemical Company. Column chromatography was performed on 
SiliCycle®SilicaFlash® P60, 40-63 µm 60 Å and in general were performed according to the guidelines reported by 
Still et al.[2] Thin layer chromatography was performed on SiliCycle® 250 µm 60 Å plates. Preparative thin layer 
chromatography was performed on SiliCycle® 2000 µm 60 Å plates. Visualization was accomplished with UV light or 
KMnO4 stain followed by heating. 
 1H NMR spectra were recorded on Varian 300 or 400 MHz spectrometers at ambient temperature unless 
otherwise stated. Data is reported as follows: chemical shift in parts per million (ppm) from CDCl3 (7.26 ppm), 
toluene-d8 (7.09, 7.0, 6.98, 2.09 ppm), multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, 
and m = multiplet), coupling constants (Hz). 13C NMR was recorded on Varian 300 or 400 MHz spectrometers (at 75 
or 100 MHz) at ambient temperature. Chemical shifts are reported in ppm from CDCl3 (77.2 ppm) or toluene-d8 
(137.86 (1), 129.4 (3), 128.33 (3), 125.49 (3), 20.4 (5) ppm).  High-resolution mass spectra (ESI) were obtained by 
Donald Dick of Colorado State University.  
 [Rh(cod)Cl]2 was purchased from Pressure Chemical Company. L1–L11 were purchased from Strem 
Chemicals. CsOAc was purchased from commercial sources and dried at 60 °C over P2O5 under high vacuum 
overnight. Tert-butyl acrylate, 1a, 1b, 3a–3e and 3i were purchased from commercial sources, distilled off of 
stabilizers and stored over 3 Å molecular sieves. 3b-d8 was purchased from Aldrich Chemical Company, distilled off 
of stabilizers and stored over 3 Å molecular sieves. 5-chlorobenzoxazole (1e) was purchased from AK Scientific. 
CD3CN was purchased from Cambridge Isotope Laboratories and stored over 3 Å molecular sieves. 2-amino phenol 
starting materials for the synthesis of benzoxazoles 1c–1d, 1f and 1h were purchased from AK Scientific. 2-amino-5-
methoxyphenol hydrochloride (for the synthesis of 1g) was purchased from Accela Chembio Inc. via Fisher 
Scientific. Teflon-lined screw caps were purchased from Fisher Scientific (03-340-14F). 
                                                                                                                                                         
[2] Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923 – 2925. 
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A.2.2 Synthesis of [Rh(cod)OAc]2[3] 
[Rh(cod)OAc]2 was synthesized according to a procedure adapted from Chatt and Venanzi:[3] A flame-dried 100 
mL round-bottom flask was charged with [Rh(cod)Cl]2  (1.04 g, 2.11 mmol, 1 equiv) and KOAc (1.04 g, 10.6 mmol, 
5.03 equiv), evaporated and backfilled with argon. Acetone (65 mL, freshly distilled over CaSO4) was added and the 
reaction was heated at reflux for 6 h, at which point near complete conversion was observed by TLC (1:1 
Hex:EtOAc, Rf [Rh(cod)Cl]2 = 0.60; Rf [Rh(cod)OAc]2 = 0.05, spots observed by UV and KMnO4). An additional 
1.03 g (4.98 equiv) KOAc was added, and the reaction was allowed to reflux overnight. At this point, the reaction 
was filtered through celite and rinsed with HPLC grade dichloromethane until all traces of orange had been washed 
from the celite. After concentration by rotary evaporation, the orange residue was recrystallized from HPLC grade 
EtOAc (~15 mL) to give [Rh(cod)OAc]2 as red orange plates (750 mg, 66% yield). The melting point was collected 
under air, and product decomposition was observed beginning at 182 °C (reported MP = 197–198 °C).[3] The mother 
liquor was concentrated to a brown residue which was further recrystallized from HPLC grade EtOAc to give a 
second crop of [Rh(cod)OAc]2 (269 mg, 24%). Rf = 0.05 (1:1 Hex:EtOAc); IR (Thin Film/NaCl) 2998, 2984, 2945, 
2867, 2838, 1573 (s), 1412 (s). 
A.2.3 Hydroheteroarylation (HH) of tert-butyl acrylate with azoles using [Rh(cod)OAc]2 (Chapter 2, Table 2.1, 
blue conditions) 
In a glove box, a 1-dram vial was equipped with a magnetic stirring bar and charged with [Rh(cod)OAc]2 (2.7 
mg, 0.005 mmol, 2.0 mol %) and dppe (4.0 mg, 0.010 mmol, 4.0 mol %). To this was added a solution of heterocycle 
1 (0.25 mmol, 1.0 equiv), tert-butyl acrylate (0.50 mmol, 2.0 equiv) and 1,3,5-trimethoxybenzene (4.2 mmol, 0.025 
mmol, 0.10 equiv) in PhMe (Aldrich 244511, 500 µL). The vial containing the resultant yellow suspension was then 
sealed with a Teflon-lined screw cap, removed from the glove box and heated to 120 °C in an aluminum heating 
block. After several minutes at 120 °C, reactions turned a homogeneous orange or dark red (with 1b). After 24 hours, 
the reactions were cooled to room temperature, concentrated, dissolved in CDCl3 and analyzed by 1H NMR 
spectroscopy (see section A.2.5). 
                                                                                                                                                         
[3]  Chatt, J.; Venanzi, L. M. J. Chem. Soc. 1957, 4735 – 4741. 
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A.2.4 Hydroheteroarylation (HH) of tert-butyl acrylate with azoles using [Rh(cod)Cl]2 and CsOAc (Chapter 2, 
Table 2.1, red conditions)[4] 
In a glove box, a 1-dram vial was equipped with a magnetic stirring bar and charged with [Rh(cod)Cl]2 (2.5 mg, 
0.005 mmol, 2 mol %), dppe (4 mg, 0.010 mmol, 4 mol %) and CsOAc (12 mg, 0.06 mmol, 25 mol %). To this, was 
added a solution of heterocycle 1 (0.25 mmol, 1.0 equiv), tert-butyl acrylate (0.50 mmol, 2.0 equiv) and 1,3,5-
trimethoxybenzene (4.20 mg, 0.025 mmol, 0.10 equiv) in PhMe (Aldrich 244511, 500 µL). The vial containing the 
resultant yellow suspension was then sealed with a teflon-lined screw cap, removed from the glove box and heated to 
120 °C in an aluminum heating block. After several minutes at 120 °C, the reactions turned a heterogeneous orange 
or dark red (with 1b). After 24 hours, the reactions were cooled to room temperature, concentrated, dissolved in 
CDCl3 and analyzed by 1H NMR spectroscopy (see section A.2.5). Particularly heterogeneous reactions were filtered 
through celite into the NMR tube prior to analysis.  
A.2.5 Hydroheteroarylation yield determination by 1H NMR spectroscopy (Chapter 2, Table 2.1) 
For accurate integration, 4 scans were collected, and d1 was set to 45 seconds to ensure complete relaxation of 
aryl resonances. All yields were determined relative to the H3CO-resonance of 1,3,5-trimethoxybenzene at 3.77 ppm. 
A.2.6 Characterization data for products 2a–2d (Chapter 2, Table 2.1) 
2a. For characterization, two representative reactions were combined and purified by 
preparative thin layer chromatography (3:1 Hex:Acetone) to give 2a as a colorless 
oil. Rf = 0.50 (3:1 Hex:Acetone); 1H NMR (300 MHz, CDCl3) δ 7.62-7.68 (m, 1H), 7.43-7.50 (m, 1H), 7.26-7.31 (m, 
2H), 3.20 (t, 2H, J = 7.5 Hz), 2.84 (t, 2H, J = 7.5 Hz), 1.42 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 171.1, 165.9, 
150.9, 141.3, 124.7, 124.2, 119.7, 110.4, 81.1, 32.1, 28.1, 24.2; IR (Thin Film/NaCl) 2979, 2933, 1731, 1616, 1574 
cm-1; LRMS (EI) m/z [C14H17NO3] ([M]+) calcd 247, found 247. 
2b. Characterization data for 2b match that reported in the literature.[4] 
 
2c. Flash column chromatography on silica gel (10:1 Hex:EtOAc)  gave 2c as a 
colorless oil (87%). Rf = 0.26 (10:1 Hex:EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.29 
                                                                                                                                                         









(d, 1H, J = 8.0 Hz), 7.17 (t, 1H, J = 8.0 Hz), 7.09 (d, 1H, J = 7.2 Hz), 3.21 (t, 2H, J = 7.4 Hz), 2.83 (t, 2H, J = 7.4 
Hz), 2.58 (s, 3H), 1.45 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 171.2, 165.0, 150.7, 140.6, 130.1, 124.8, 124.3, 107.7, 
81.1, 32.4, 28.2, 24.4, 16.6; IR (Thin Film/NaCl) 2978, 1731, 1150 cm-1; LRMS (EI) m/z [C15H19NO3] ([M]+)  calcd 
261, found 261. 
2d. For characterization, two representative reactions were combined and purified by 
preparative thin layer chromatography (2% EtOAc in DCM) to give 3d as a colorless 
oil. This was found to be the best purification method on small scale as the product is 
difficult to separate from residual starting material. Rf = 0.35 (98:2 DCM:EtOAc); 1H NMR (400 MHz, CDCl3) δ 
7.47 (d, 1H, J = 7.6 Hz), 7.18 (t, 1H, J = 7.6 Hz), 7.08 (d, 1H, J = 7.6 Hz), 3.21 (t, 2H, J = 7.6 Hz), 2.85 (t, 2H, J = 
7.6 Hz), 2.50 (s, 3H), 1.44 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 171.2, 165.6, 150.2, 141.0, 125.7, 124.2, 121.0, 
117.0, 81.1, 32.2, 28.2, 24.3, 15.3; IR (ATR) 2978, 2929, 1729, 1612, 1574, 1141 cm-1; LRMS (ESI+APCI) m/z 
[C15H20NO3]+ ([M+H]+)  calcd 262.0, found 262.1. 
A.2.7 Synthesis of 1b-D (Chapter 2, eq. 10 and Figure 2.4a) 
1b-D. To a solution of benzothiazole (1b) (250 mg, 1.85 mmol, 1.0 equiv) in THF (15 mL) at -78 
°C was added tert-butyl lithium (2.0 mL, 1.4 M in pentane, 2.8 mmol, 1.5 equiv) via syringe 
pump over 1 hour. An instantaneous color change from clear to yellow was observed. The reaction mixture was 
stirred for an additional 30 minutes at -78 °C, and then MeOH-d4 (1.5 mL) was added dropwise at -78 °C. The 
reaction mixture was adsorbed onto silica gel and purified by flash column chromatography (7:1 Hex:EtOAc) to give 
42 mg (0.31 mmol, 16%) 1b-D as a light yellow oil: Rf = 0.22 (5:1 Hex:EtOAc); 1H NMR (300 MHz, CDCl3) δ 8.13-
8.16 (m, 1H), 7.95-7.98 (m, 1H), 7.42-7.55 (m, 2H) (Less than 1% 1H observed at δ 9.00) (Figure A.2.1); 2H NMR 
(300 MHz, PhMe-d8) δ 8.23 (s) (see Chapter 2, Figure 2.4a). Note: the azole C–H resonance appears at δ = 9.00 ppm 
in CDCl3 and at δ = 8.23 ppm in PhMe-d8. 
 








A.2.8 C–H reversibility experiment between 1c and 1b-D (Chapter 2, eq. 10 and Figure 2.4a) 
A.2.8.1 Reaction set-up 
[Rh(cod)OAc]2 (3.2 mg, 0.006 mmol, 4.0 mol %) and dppe (4.8 mg, 0.012 mmol, 8.0 mol %) were weighed into 
a J. Young tube in the glove box. To this was added a solution of 1c (20 mg, 0.15 mmol, 1.0 equiv) and tert-butyl 
acrylate (88 µL, 0.60 mmol, 4.0 equiv) in 480 µL PhMe and 120 µL of a solution of 1b-D (42 mg, 0.31 mmol) and 
1,3,5-trimethoxybenzene (8.2 mg, 0.05 mmol) in 200 µL PhMe. The J. Young tube was sealed and removed from the 
box. 1H NMR analysis (300 MHz) of the reaction mixture prior to heating showed no 1H resonance at δ = 8.36 ppm, 
and 2H NMR showed a corresponding single 2H resonance at δ = 8.23 ppm. The NMR tube was suspended in a 120 
°C oil bath, and the reaction was removed periodically for 1H and 2H NMR analysis (300 MHz). Crossover peaks for 
1b-H and 1c-D began to populate the 1H and 2H spectra over time (see Chapter 2, Figure 2.4a).  
A.2.8.2 Determination of percent conversion of 1b-D 
Percent conversion of 1b-D was approximated by comparing the integration values in the 1H NMR for the 
aromatic resonance of starting material 1b-D at δ = 8.00 (J = 8.1 Hz) with the corresponding aromatic resonance of 
product 2b at δ = 7.87 (J = 8.7 Hz) (Figure A.2.2).  
Figure A.2.2 1H NMR of eq. 10 (Chapter 2) after 130 h at 120 °C. Percent conversion of 1b-D was determined by 
comparison of integration values for starting material 1b-D at δ = 8.00 (J = 8.1 Hz) with the corresponding aromatic 
resonance of product 2b at δ = 7.87 (J = 8.7 Hz) 
A.2.8.3 Determination of percent 2H incorporation in products 2b and 2c 
The crude reaction mixture from the reversibility experiment was concentrated, dissolved in dichloromethane 
and pipetted onto a preparative TLC. Preparative TLC (2 x 13:1 Hex:Acetone) allowed fairly clean separation of 2b 
(contaminated with 1b) and 2c (contaminated with some 2b). 2H incorporation was determined by 1H NMR analysis 
of fairly pure 2b and 2c (Figure A.2.3 and A.2.4).  
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Figure A.2.3 1H NMR spectrum of 2b (contaminated with some 1b) 
  
Figure A.2.4 1H NMR spectrum of 2c (contaminated with about 10 % 2b (green dot)). A corresponding amount 
(0.22) is subtracted from blue integral of 2c (i.e. 2.22 – 0.22), since the other methylene resonance of 2b underlies it. 
A.2.9 General procedure for the synthesis of benzoxazoles 1c–1d and 1f–1h 
Benzoxazoles 1c–1d and 1f–1h were prepared from the corresponding 2-amino phenols according to a modified 
known procedure:[5] To a flame-dried, round-bottom flask equipped with reflux condenser was charged the 
appropriate 2-amino phenol derivative (1.0 equiv) and trimethyl orthoformate (Aldrich 108456, 12 equiv). The dark 
red reaction mixture was heated to 110 °C overnight. After cooling to room temperature, trimethylorthoformate was 
removed by rotary evaporation, and the crude residue was purified by column chromatography, distillation or a 
combination of both. 
                                                                                                                                                         










A.2.10 Characterization data for benzoxazoles 1c–1d and 1f–1h 
1c.[5–6] Flash column chromatography on silica gel (2 x 7:1 Hex:EtOAc) followed by repeated (2x) 
kugelrohr distillation under reduced pressure yielded a colorless liquid (55%). Rf = 0.24 (10:1 
Hex:EtOAc); IR (thin film/NaCl) 3062, 3105, 3063, 3032, 2924, 1623, 1519, 1242, 1071 cm-1; LRMS 
(EI) m/z [C8H7NO]+ ([M]+) calcd 133, found 133. 1H and 13C NMR spectra match those reported in the literature.[5–6] 
Full characterization data available in Ref. 6a. 
1d. Kugelrohr distillation followed by flash column chromatography on silica gel (8:1 Hex:EtOAc) 
provided 1d as a white solid (61%). Rf = 0.22 (10:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3) δ 
8.08 (s, 1H), 7.61 (d, 1H, J = 8.0 Hz), 7.27 (t, 1H, J = 7.6 Hz), 7.18 (d, 1H, J = 7.2 Hz), 2.55 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 152.4, 149.4, 139.7, 126.6, 124.6, 121.7, 118.0, 15.3; IR (ATR) 3085, 2922, 1511, 
1489 cm-1; LRMS (ESI+APCI) m/z [C8H8NO]+ ([M+H]+) calcd 134.1, found 134.0. 
1f.[6a] Flash column chromatography on silica gel (4:1 ! 3:1 Hex:Et2O) followed by kugelrohr 
distillation yielded a white solid (17%) Note: this compound is quite volatile, and a good portion 
was lost while drying under high vacuum after the chromatography step. Rf = 0.31 (3:1 Hex:Et2O); 19F NMR (376 
MHz, CDCl3) δ -114.7 (m). All other characterization data (1H NMR, 13C NMR, IR and MS) match those reported in 
the literature.[6a]  
1g.[6a,6c] Prepared with 2-amino-5-methoxyphenol hydrochloride according to the general 
procedure but with additional 1.1 equiv NEt3 to liberate the HCl salt. Flash column 
chromatography on silica gel (2:1 ! 1:1 Hex:Et2O) yielded a white solid (90%). Full characterization data available 
in Ref. 6a. 
1h.[6] Flash column chromatography on silica gel (3:1 Hex:EtOAc) followed by kugelrohr 
distillation under reduced pressure yielded a white solid (35%). Rf = 0.25 (3:1 Hex:EtOAc); 
IR (ATR) 3123, 3013, 2977, 2944, 2888, 2835, 1612, 1515 cm-1; LRMS (ESI + APCI) m/z [C8H8NO2]+ ([M+H]+) 
calcd 150.1, found 150.1; 1H NMR and 13C NMR spectra match those reported in the literature.[6] Full 
characterization data available in Ref. 6a.  
                                                                                                                                                         
[6]  (a) Lee, J. J.; Kim, J.; Jun, Y. M.; Lee, B. M.; Kim, B. H. Tetrahedron 2009, 65, 8821 – 8831.  
 (b) Guo, S.; Qian, B.; Xie, Y.; Xia, C.; Huang, H. Org. Lett. 2011, 13, 522 – 525.  
















A.2.11 Preparation of α-substituted acrylates 3g, 3h and 3j 
3a-e and 3i were purchased from commercial sources, and 3f was prepared according to a known procedure.[7] 
Full characterization data for 3f is found in Ref. 7b. 
3g was prepared according to the two-step sequence below: 
 
A3 was prepared according to a procedure described by Gani et al:[8] To a solution of NaOEt 
(126.5 mmol, 1.1 equiv, prepared by addition of Na(0) to EtOH) in EtOH (45 mL) was added 
ethyl acetoacetate (A1) (15.0 g, 115 mmol, 1.0 equiv) over about 1 minute. To the resultant 
yellow solution was then slowly added butyl bromide (A2) (16.0 mL, 149.5 mmol, 1.3 equiv, 
washed with NaHCO3 and distilled before use). The reaction was heated to reflux for 24h at which point it was 
cooled and partitioned between Et2O and water in a separatory funnel. The aqueous layer was extracted with Et2O 
two times more, and the combined organic extracts were washed with brine and dried (MgSO4). Distillation under 
reduced pressure yielded 9.19g (43%) of crude product (contaminated with about 10% dialkylated product), which 
was taken to the next step without further purification. 
3g was prepared from A3 according to a procedure modified from one described by Gellman et 
al:[7a]  To a solution of LiHMDS (7.43 g, 44.4 mmol, 1.1 equiv) in THF (250 mL) at -78 °C was 
added a solution of A3 (7.53 g, 40.4 mmol, 1.0 equiv) in THF (45 mL) via addition funnel. The 
reaction was stirred for an additional 75 minutes at -78 °C, and then paraformaldehyde (5.70 g, excess) was added in 
one portion. The ice bath was removed, and the reaction was allowed to stir at room temperature for an additional 4 h. 
At this point, the reaction was filtered through celite to remove excess paraformaldehyde and concentrated by rotary 
evaporation. The crude reaction mixture was purified by flash column chromatography on silica gel (30:1 ! 10:1 
Hex:EtOAc), and the purest fractions were combined to give 3g as a clear liquid (2.41 g, 15.4 mmol, 12% over 2 
steps): Rf = 0.20 (40:1 Hex:EtOAc); 1H NMR (400 MHz, CDCl3) δ 6.11 (m, 1H), 5.49 (m, 1H), 4.19 (q, 2H, J = 7.2 
                                                                                                                                                         
[7]  (a) Lee, H.; Park, J.; Kim, B. M.; Gellman, S. H. J. Org. Chem. 2003, 68, 1575 – 1578.  
 (b) Biju, A. T.; Padmanaban, M.; Wurz, N. E.; Glorius, F. Angew. Chem. Int. Ed. 2011, 50, 8412 – 8415. 




O 1) NaOEt, EtOH, 23 °C
2) Me Br









1) LiHMDS, THF, -78 °C
2) paraformaldehyde
-78 °C → 23 °C










Hz), 2.29 (m, 2H), 1.40-1.48 (m, 2H), 1.29-1.37 (m, 2H), 1.29 (t, 3H, J = 7.2 Hz), 0.90 (t, 3H, J = 7.2 Hz); 13C NMR 
(100 MHz, CDCl3) δ 167.5, 141.2, 124.2, 60.6, 31.7, 30.7, 22.4, 14.3, 14.0; IR (ATR) 2958, 2931, 2873, 1716, 1631, 
1153 cm-1; LRMS (EI) m/z [C9H16O2]+ ([M]+) calcd 156, found 156. 
3h was prepared according to the two-step procedure of Gellman et al.:[7a] 
 
 
A5. To a solution of KOtBu (3.53g, 31.4 mmol, 1.05 equiv) in THF (80 mL) at 0 °C was added 
ethyl acetoacetate (A1) (3.93 g, 30.2 mmol, 1.01 equiv) slowly. HOtBu (287 µL, 3.0 mmol, 
0.10 equiv) was then added, and the reaction mixture was allowed to stir 30 minutes at 0 °C. 
Iodide A4 (5.52 g, 30.0 mmol, 1.0 equiv, distilled before use) was added in one portion, and the 
ice bath was removed. The reaction was heated to reflux for 24 h and then cooled to room temperature. After removal 
of THF by rotary evaporator, the reaction mixture was partitioned between Et2O and saturated NaHCO3. The aqueous 
layer was extracted with Et2O two times more, and the combined organic layers were washed with brine and dried 
(MgSO4). Flash column chromatography on silica gel (8% EtOAc in Hex) yielded 3.18 g of crude product, which was 
taken to the next step without further purification. 
3h. To a solution of A5 (3.18 g, 17.1 mmol, 1.0 equiv) in THF (110 mL) at -78 °C was added a 
solution of LiHMDS (3.15 g, 18.7 mmol, 1.1 equiv) in THF (20 mL). The reaction mixture was 
allowed to stir for 30 minutes at -78 °C, and then paraformaldehyde (2.40 g, excess) was added as a 
solid in one portion. The ice bath was removed, and the reaction was allowed to stir at room temperature overnight. 
At this point, the reaction was filtered through celite to remove excess paraformaldehyde and concentrated by rotary 
evaporation. The crude reaction mixture was purified by flash column chromatography on silica gel (Hex ! 2% ! 
4% ! 8% ! 15% EtOAc in Hex) to give 3h as a clear liquid (1.76 g, 11.3 mmol, 37% over two steps): Rf = 0.32 
(4% EtOAc in Hex); 1H NMR (400 MHz, CDCl3) δ 6.15 (d, 1H, J = 1.6 Hz), 5.47 (m, 1H), 4.19 (q, 2H, J = 7.2 Hz), 
2.18 (dd, 1H, J = 7.2, 1.2 Hz), 1.79 (m, 1H), 1.30 (t, 3H, J = 7.2 Hz), 0.89 (d, 6H, J = 6.8 Hz); 13C NMR (100 MHz, 
CDCl3) δ 167.7, 140.1, 125.6, 60.7, 41.5, 27.4, 22.4, 14.4; IR (ATR) 2957, 2934, 2870, 1715, 1630 cm-1; LRMS (EI) 
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3j was prepared according to the two-step procedure of Gellman et al.:[7a] 
 
A7. To a solution of KOtBu (3.70 g, 33.0 mmol, 1.10 equiv) in THF (80 mL) at 0 °C was 
added ethyl acetoacetate (A1) (3.88 g, 29.8 mmol, 1.01 equiv) slowly. HOtBu (287 µL, 3.0 
mmol, 0.10 equiv) was then added, and the reaction mixture was allowed to stir 30 minutes 
at 0 °C. Bromide A6 (7.50 g, 29.6 mmol, 1.0 equiv, prepared from 3-bromo-1-propanol 
according to a known procedure)[9] was added in one portion, and the ice bath was removed. The reaction was heated 
to reflux for 36 h and then cooled to room temperature. After removal of THF by rotary evaporator, the reaction 
mixture was partitioned between Et2O and H2O. The aqueous layer was extracted with Et2O two times more, and the 
combined organic layers were washed with brine and dried (MgSO4). Flash column chromatography on silica gel 
(Hex ! 5% ! 8% ! 10% ! 15% EtOAc in Hex) yielded 4.89 g of crude product, which was taken to the next step 
without further purification. 
3j. To a solution of A7  (4.89 g, 16.2 mmol, 1.0 equiv) in THF (110 mL) at -78 °C was added a 
solution of LiHMDS (2.97 g, 17.8 mmol, 1.1 equiv) in THF (20 mL). The reaction mixture was 
allowed to stir for 30 minutes at -78 °C, and then paraformaldehyde (2.30 g, excess) was added as a 
solid in one portion. The ice bath was removed, and the reaction was allowed to stir at room temperature overnight. 
At this point, the reaction was filtered through celite to remove excess paraformaldehyde and concentrated by rotary 
evaporation. The crude reaction mixture was purified by flash column chromatography on silica gel (Hex ! 2% ! 
4% ! 6% ! 10% EtOAc in Hex) to yield 3j as a clear liquid (3.59 g, 44% over two steps). Characterization data for 
3j match that reported in the literature.[10] 
  
                                                                                                                                                         
[9]  Trapella, C.; Fischetti, C.; Pela, M.; Lazzari, I.; Guerrini, R.; Calo, G.; Rizzi, A.; Camarda, V.; Lambert, D. G.; McDonald, 
J.; Regoli, D.; Salvadori, S. Bioorg. Med. Chem. 2009, 17, 5080 – 5095. 
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A.2.12 Initial optimization of the asymmetric HH reaction of 4-methyl benzoxazole (1c) and ethyl methacrylate 
(3a) (Chapter 2, Table 2.2) 
A.2.12.1 Reaction set-up 
In a glove box, a 1 dram vial equipped with magnetic stirring bar was charged [Rh(cod)OAc]2 (1.4 mg, 2.6 µmol, 
2 mol %) and ligand (5.2 µmol, 4 mol %). To this was added a solution of 4-methylbenzoxazole (1c) (16.6 mg, 14.7 
µL, 0.125 mmol, 1 equiv) and 4,4’-di-tert-butylbiphenyl (3.3 mg, 12.5 µmol, 0.10 equiv) in 250 µL of the appropriate 
solvent. Ethyl methacrylate (3a) (62 µL, 4 equiv up to 124 µL, 8.0 equiv) was then added, and the vial was sealed 
with a Teflon-lined screw cap. At this point, the vial was removed from the glove box and placed in an aluminum 
block set to the indicated temperature. After the reaction was heated for the indicated amount of time, it was cooled to 
room temperature. A 15 µL aliquot of the crude reaction mixture was removed and diluted with 500 µL 1:1 
Hex:iPrOH. Note: in the case that solid precipitated at this point—acrylate polymerized under some conditions listed 
in Table 1—the sample was filtered prior to analysis. Percent yield and percent ee of 4ca was determined with 
respect to 4,4’-di-tert-butylbiphenyl by LC analysis on a chiral stationary phase as described below. 
A.2.12.2 Analysis of the HH reaction of 4-methylbenzoxazole (1c) and ethyl methacrylate (3a) by chiral HPLC 
HPLC Method: 4,4’-di-tert-butylbiphenyl (DTBB), ethyl methacrylate (3a), 4-methylbenzoxazole (1c) and both 
enantiomers of product 4ca are separated by the following method: Chiracel IB column, 94:6 Hex:10% iPrOH in 
Hex, 1 mL/min. Note: See section A.2.19 for HPLC traces of racemic and enantioenriched 4ca. 
 DTBB: 3.5 min 
 Ethyl methacrylate (3a): 3.9 min (3a has a very low absorbance) 
 4-methylbenzoxazole (1c): 6.0 min 
 First enantiomer 4ca: 7.3 min 
 Second enantiomer 4ca: 8.1 min 
Response factor calculation for 4ca: Using stock solutions of appropriate concentrations of 4,4’-di-tert-
butylbiphenyl (DTBB) and racemic 4ca, each of five HPLC vials was charged with DTBB (2.0 mg, 7.5 µmol), 
increasing amounts of racemic 4ca (to mimic 5, 10, 20, 40 and 80 percent yield 4ca assuming 20 percent loading of 
DTBB) and enough 1:1 Hex:iPrOH to make a total volume of 1000 µL: 
  Vial 1: 0.46 mg, 1.87 µmol 4ca 
  Vial 2: 0.93 mg, 3.75 µmol 4ca 
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  Vial 3: 1.86 mg, 7.51 µmol 4ca 
  Vial 4: 3.71 mg, 15.0 µmol 4ca 
  Vial 5: 7.43 mg, 30.0 µmol 4ca 
Each of these five samples was analyzed by chiral HPLC according to the method above. The areas of both 
enantiomers of 4ca were summed together to give the total area of product 4ca. The ratio (Area 4ca:Area DTBB) (Y-
axis) was plotted against the ratio [4ca]:[DTBB] (X-axis) for various wavelengths (DAD A–D) to give a response 
factor curve (Figure A.2.5). The response factor curve was found to be highly linear for all wavelengths in the region 
analyzed, and the slope of each line gave the response factor, Rf  4ca for a given wavelength (Figure A.2.5): 
 Rf 4ca DAD A (254 nm): 0.17 
 Rf 4ca DAD B (254 nm): 0.20 
 Rf 4ca DAD C (210 nm): 0.69 
 Rf 4ca DAD D (230 nm): 1.18 
Percent yield 4ca: Yields of 4ca were either reported as averages from those determined at each of these four 
wavelengths or from the wavelength that provided the cleanest spectrum.  
Percent ee 4ca: Percent ee of 4ca was determined simply by subtraction of the areas of 4ca enantiomers. 
 
 





































A.2.13 General procedure for second generation optimization of the asymmetric HH reaction of 4-methyl 
benzoxazole (1c) and ethyl methacrylate (3a) (Chapter 2, Table 2.3) 
In a glove box, a 1.5 dram vial equipped with magnetic stirring bar was charged [Rh(cod)OAc]2 (6.8 mg, 12.6 
µmol, 5 mol %) and ligand (25.2 µmol, 10 mol %). To this was added a solution of 4-methylbenzoxazole (1c) (33.3 
mg, 29.5 µL, 0.25 mmol, 1.0 equiv), 4,4’-di-tert-butylbiphenyl (6.6 mg, 25.0 µmol, 0.10 equiv) and ethyl 
methacrylate (3a) (228 mg, 250 µL, 2.0 mmol, 8.0 equiv) in CH3CN (500 µL). The vial was sealed with a Teflon-
lined screw cap and removed from the glove box. The reaction was heated at 100 °C in an aluminum block for 24 h. 
After cooling to room temperature, a 15 µL aliquot of the crude reaction mixture was removed and diluted with 500 
µL 1:1 Hex:iPrOH. Percent yield and percent ee were determined as described above for the initial reaction 
optimization (section A.2.12.2).  
Note: It was found that small changes in [Rh(cod)OAc]2 to ligand ratio can influence the rate of formation of 
4ca rather dramatically. For acceptable reproducibility, it was necessary to double the scale from 0.125 mmol 1c 
(initial reaction optimization, section A.2.12.1) to 0.25 mmol 1c. 
A.2.14 General procedure for the asymmetric HH of methacrylate derivatives 3 with benzoxazoles 1 (Chapter 2, 
Table 2.4) 
In a glove box, a 1.5 dram vial equipped with magnetic stirring bar was charged [Rh(cod)OAc]2 (6.8 mg, 12.6 
µmol, 0.05 equiv), CTH-(R)-xylyl-P-Phos (18.9 mg, 25.2 µmol, 0.10 equiv) and CsOAc (12.0 mg, 62.5 µmol, 0.025 
equiv) where applicable. To this was added a solution of benzoxazole 1 (0.25 mmol, 1.0 equiv), 4,4’-di-tert-
butylbiphenyl (6.6 mg, 25.0 µmol, 0.10 equiv) and acrylate derivative (3a) (2.0 mmol, 8.0 equiv) in CH3CN (500 µL). 
The vial was sealed with a Teflon-lined screw cap and removed from the glove box. The reaction was heated at 100 
°C in an aluminum block for 48 h unless otherwise indicated. After cooling to room temperature, the reaction mixture 
was either concentrated directly (without CsOAc) or filtered through celite prior to concentration (with CsOAc). 
Crude reaction mixtures were analyzed by 1H NMR spectroscopy if desired. Crude reaction mixtures were then 
adsorbed onto silica and purified by flash column chromatography on silica gel to give the corresponding products 4. 
Note 1: Racemic products were prepared in the same fashion but with 9.8 mg (12.6 µmol, 0.05 equiv) CTH-(R)-
xylyl-P-Phos and 9.8 mg (12.6 µmol, 0.05 equiv) CTH-(S)-xylyl-P-Phos. 
Note 2: Whereas most reactions were performed by placing the 1.5 dram vial in the bottom of the aluminum 
block, it was found that slight improvements in ee for epimerizable or lower ee products (4cc–4cd, 4aa and 4ea–4ha) 
 85 
could be achieved by filling the aluminum well with sand to such a level that the reaction solvent reached the top of 
the aluminum well.  
A.2.15 Comparison of reaction efficiency in presence or absence of CsOAc (Chapter 2, Table 2.4, 4cf and 4aa) 
Because subtle changes in rhodium to ligand ratio is known to influence reaction efficiency (vide supra), 
comparison of reactions with and without CsOAc were performed with the same stock solution of [Rh(cod)OAc]2, 
CTH-(R)-xylyl-P-Phos, DTBB, benzoxazole 1 and acrylate 3. For instance, for the comparision of the reaction of 
benzoxazole (1a) and (3a), the following procedure was used: 
15.5 mg (0.05 equiv) [Rh(cod)OAc]2, 43.5 mg (0.10 equiv) CTH-(R)-xylyl-P-Phos, 68 mg (58 µL, 1.0 equiv) 1a, 
15.4 mg (0.10 equiv) DTBB, 526 mg (574 µL, 8.0 equiv) 3a were dissolved in 1150 µL CH3CN. 807 µL of the 
resultant solution was added to either an empty 1.5 dram vial or a 1.5 dram vial containing 12.0 mg (62.5 µmol, 0.25 
equiv) CsOAc. Both vials were sealed with a Teflon-lined screw cap, removed from the box and heated to 100 °C in 
an aluminum block for 48 h. A 15 µL aliquot was removed from each reaction and subjected to chiral HPLC analysis 
(Chiracel IC column, 80:20 Hex:iPrOH, 1.0 mL/min, see characterization data for 4aa in section A.2.16 and HPLC 
data for 4aa in section A.2.19) to determine percent ee of 4aa. The reaction without CsOAc was then concentrated 
directly, whereas the reaction with CsOAc was filtered through celite prior to concentration. Percent yield of 4aa was 
determined with respect to DTBB by 1H NMR analysis of the crude reaction mixture. 
A.2.16 Characterization data for products 4 
4ca. Flash column chromatography on silica gel (7:1 Hex:EtOAc) yielded a colorless 
oil (88%). Rf = 0.20 (7:1 Hex:EtOAc); HPLC analysis – Chiracel IB column, 94:6 
Hex:10% iPrOH in Hex, 1.0 mL/min, major enantiomer: 8.1 min, minor enantiomer: 
7.3 min, 94% ee; [α]D25 = +13.7° (c = 0.995 g/100 mL, EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.26 (d, 1H, J = 8.0 
Hz), 7.15 (m, 1H), 7.07 (d, 1H, J = 7.6 Hz), 4.08-4.20 (m, 2H), 3.32 (dd, 1H, J = 15.2, 6.8 Hz), 3.12 (m, 1H), 3.01 
(dd, 1H, J = 15.2, 7.2 Hz), 2.56 (s, 3H), 1.28 (d, 3H, J = 7.2 Hz), 1.20 (t, 3H, 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 
175.0, 164.2, 150.7, 140.6, 130.2, 124.8, 124.4, 107.8, 60.9, 37.9, 32.4, 17.2, 16.6, 14.2; IR (ATR) 2979, 2937, 1732, 
1610 cm-1; LRMS (ESI + APCI) m/z [C14H18NO3]+ ([M+H]+) calcd 248.1, found 248.1. 
4cb. Flash column chromatography on silica gel (7:1 ! 5:1 Hex:EtOAc) yielded a 
colorless oil (68%). Rf = 0.17 (7:2 Hex:Et2O); HPLC analysis – Chiracel IB column, 














enantiomer: 8.6 min, 94% ee; [α]D25 = +12.4° (c = 1.835 g/100 mL, CDCl3); 1H NMR (400 MHz, CDCl3) δ 7.29 (d, 
1H, J = 8.0 Hz), 7.18 (m, 1H), 7.09 (d, 1H, J = 7.6 Hz), 3.71 (s, 3H), 3.35 (dd, 1H, J = 15.2, 6.8 Hz), 3.17 (m, 1H), 
3.04 (dd, 1H, J = 15.2, 7.6 Hz), 2.59 (s, 3H), 1.31 (d, 3H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 175.5, 164.1, 
150.7, 140.6, 130.2, 124.9, 124.4, 107.8, 52.2, 37.8, 32.4, 17.2, 16.6; IR (ATR) 2976, 2952, 2923, 1736, 1625 cm-1; 
LRMS (ESI + APCI) m/z [C13H16NO3]+ ([M+H]+) calcd 234.1, found 234.1. 
4cc. Flash column chromatography on silica gel (4:1 ! 3:1 Hex:Et2O) yielded a 
colorless oil (98%). Rf = 0.22 (4:1 Hex:Et2O); HPLC analysis – Chiracel IB column, 
90:10 Hex:iPrOH, 1.0 mL/min, major enantiomer: 5.3 min, minor enantiomer: 4.9 
min, 92% ee; [α]D25 = +6.2° (c = 3.560 g/100 mL, CDCl3); 1H NMR (400 MHz, CDCl3) δ 7.26-7.30 (m, 6H), 7.18 (t, 
1H, J = 7.6 Hz), 7.09 (d, 1H, J = 7.6 Hz), 5.15 (s, 2H), 3.37 (dd, 1H, J = 15.6, 7.2 Hz), 3.23 (m, 1H), 3.06 (dd, 1H, J 
= 15.6, 7.2 Hz), 2.58 (s, 3H), 1.34 (d, 3H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 174.8, 164.0, 150.7, 140.6, 
135.9, 130.2, 128.6, 128.3, 128.2, 124.9, 124.4, 107.8, 66.7, 37.9, 32.4, 17.2, 16.6; IR (ATR) 3063, 3033, 2975, 2938, 
1734 cm-1; LRMS (ESI + APCI) m/z [C19H20NO3]+ ([M+H]+) calcd 310.1, found 310.2. 
4cd. Flash column chromatography on silica gel (1:1 Hex:Et2O) yielded a colorless oil 
(54%). Rf = 0.20 (3:1 Hex:EtOAc); HPLC analysis – Chiracel IB column, 98:2 
Hex:iPrOH, 1.0 mL/min, major enantiomer: 13.4 min, minor enantiomer: 12.3 min, 84% 
ee; [α]D25 = +29.7° (c = 1.105 g/100 mL, CDCl3); 1H NMR (400 MHz, CDCl3) δ 7.33 (d, 1H, J = 8.0 Hz), 7.23 (m, 
1H), 7.13 (d, 1H, J = 7.2 Hz), 3.32-3.40 (m, 2H), 3.13-3.20 (m, 1H), 2.60 (s, 3H), 1.48 (d, 3H, J = 6.8 Hz); 13C NMR 
(100 MHz, CDCl3) δ 161.4, 150.8, 140.4, 130.7, 125.2, 125.0, 121.6, 108.0, 33.2, 23.9, 18.0, 16.6; IR (ATR) 3062, 
3033, 2984, 2942, 2244, 1610 cm-1; LRMS (ESI + APCI) m/z [C12H13N2O]+ ([M+H]+) calcd 201.1, found 201.1. 
4ce. Flash column chromatography on silica gel (2 x 5:1 pentane:Et2O) yielded a light 
yellow oil (15%, Note: 1H NMR with respect to DTBB shows that 4ce is formed in 
41% yield, but it is difficult to separate from starting material 1c). Rf = 0.17 (5:1 
pentane:Et2O); HPLC analysis – Chiracel IC column, 90:10 Hex:iPrOH, 0.7 mL/min, 1st enantiomer: 7.8 min, 2nd 
enantiomer: 8.3 min, < 5 % ee; 1H NMR (300 MHz, CDCl3) δ 7.29 (d, 1H, J = 8.1 Hz), 7.17 (m, 1H), 7.08 (d, 1H, J = 
7.5 Hz), 4.14 (q, 2H, J = 7.2 Hz), 3.65 (m, 1H), 3.03 (dd, 1H, J = 16.2, 6.9 Hz), 2.68 (dd, 1H, J = 16.2, 7.5 Hz), 2.59 



















130.3, 124.8, 124.3, 107.8, 60.8, 39.2, 31.0, 18.6, 16.6, 14.3; IR (ATR) 2979, 2935, 1734, 1625, 1608 cm-1; LRMS 
(ESI + APCI) m/z [C14H18NO3]+ ([M+H]+) calcd 248.1, found 248.1. 
4cf. Flash column chromatography on silica gel (16:3 ! 4:1 ! 2:1 Hex:Et2O) 
yielded a light golden oil (65%). Rf = 0.18 (16:3 Hex:Et2O); HPLC analysis – 
Chiracel IB column, 94:6 Hex:10% iPrOH in Hex, 1.0 mL/min, major enantiomer: 
13.8 min, minor enantiomer: 17.1 min, 93% ee; [α]D25 = -2.89° (c = 2.395 g/100 mL, CDCl3);[11] 1H NMR (400 MHz, 
CDCl3) δ 7.26-7.30 (m, 3H), 7.15-7.22 (m, 4H), 7.08 (d, 1H, J = 7.2 Hz), 3.64 (s, 3H), 3.36-3.45 (m, 1H), 3.25-3.31 
(m, 1H), 3.06-3.15 (m, 2H), 2.93 (dd, 1H, J = 13.6, 7.2 Hz), 2.56 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 174.4, 
163.9, 150.7, 140.6, 138.2, 130.3, 129.2, 128.7, 126.8, 124.9, 124.4, 107.8, 52.1, 45.1, 38.1, 30.3, 16.6; IR (ATR) 
3062, 3028, 2950, 2923, 2856, 1736, 1624 cm-1; LRMS (ESI + APCI) m/z [C19H20NO3]+ ([M+H]+) calcd 310.1, found 
310.1. 
4cg. Flash column chromatography on silica gel (10:1 Hex:EtOAc) yielded a colorless 
oil (93%). Rf = 0.22 (DCM); HPLC analysis – Chiracel IC column, 98:2 Hex:iPrOH, 
1.0 mL/min, major enantiomer: 9.9 min, minor enantiomer: 8.9 min, 95% ee; [α]D25 = 
+4.4° (c = 2.595 g/100 mL, CDCl3); 1H NMR (400 MHz, CDCl3) δ 7.28 (d, 1H, J = 
8.0 Hz), 7.17 (m, 1H), 7.08 (d, 1H, J = 7.6 Hz), 4.09-4.21 (m, 2H), 3.24-3.31 (m, 1H), 3.00-3.10 (m, 2H), 2.58 (s, 
3H), 1.71-1.77 (m, 1H), 1.59-1.64 (m, 1H), 1.28-1.35 (m, 4H), 1.20 (t, 3H, J = 7.2 Hz), 0.86-0.90 (m, 3H); 13C NMR 
(100 MHz, CDCl3) δ 174.5, 164.1, 150.5, 140.4, 130.0, 124.7, 124.2, 107.6, 60.6, 43.3, 31.8, 30.9, 29.0, 22.4, 16.4, 
14.1, 13.8; IR (ATR) 2957, 2931, 2861, 1732 cm-1; LRMS (ESI + APCI) m/z [C17H24NO3]+ ([M+H]+) calcd 290.2, 
found 290.1. 
4ch. The crude reaction mixture was dried under high vacuum overnight to remove 
residual benzoxazole 1c, since it coelutes with 4ch. Flash column chromatography on 
silica gel (7:1 ! 6:1 Hex:Et2O) yielded a clear oil (85%). Rf = 0.32 (5:1 Hex:Et2O); 
                                                                                                                                                         
[11]  Compounds 4cf and 4cj have low negative specific rotations, whereas all other products 4 (made with same antipode of 
chiral ligand) have low to moderate positive specific rotations. It is not clear whether the observed negative specific rotations 
of 4cf and 4cj reflect a true, negative specific rotation or whether the observed negative specific rotation arises simply 
because the magnitude of specific rotation for these products is small relative to experimental error. In terms of HPLC data, 
4cj is consistent with that of other compounds: the major enantiomer elutes second. 4cf is different than other compounds: 




















HPLC analysis – Chiracel IC column, 98:2 Hex:iPrOH, 1.0 mL/min, major enantiomer: 10.2 min, minor enantiomer: 
9.4 min, 94% ee; [α]D25 = +5.6° (c = 3.070 g/100 mL, CDCl3); 1H NMR (400 MHz, CDCl3) δ 7.28 (d, 1H, J = 8.0 
Hz), 7.17 (m, 1H), 7.08 (d, 1H, J = 7.6 Hz), 4.09-4.21 (m, 2H), 3.19-3.30 (m, 1H), 3.03-3.14 (m, 2H), 2.58 (s, 3H), 
1.59-1.77 (m, 2H), 1.34-1.41 (m, 1H), 1.20 (t, 3H, J = 7.2 Hz), 0.90-0.94 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 
175.0, 164.1, 150.7, 140.5, 130.2, 124.8, 124.4, 107.8, 60.7, 41.8, 41.6, 31.7, 26.1, 23.0, 22.1, 16.6, 14.3; IR (ATR) 
3061, 2957, 2930, 2871, 1732, 1624 cm-1; LRMS (ESI + APCI) m/z [C17H24NO3]+ ([M+H]+) calcd 290.2, found 
290.2. 
4ci. Flash column chromatography on silica gel (DCM ! 6% ! 12% EtOAc in 
DCM) yielded a colorless oil (60%). Rf = 0.23 (6% EtOAc in DCM); HPLC analysis 
– Chiracel IC column, 80:20 Hex:iPrOH, 1.0 mL/min, major enantiomer: 11.6 min, 
minor enantiomer: 10.8 min, 69% ee; [α]D25 = +7.2° (c = 2.030 g/100 mL, CDCl3); 1H NMR (400 MHz, CDCl3) δ 
7.29 (d, 1H, J = 7.6 Hz), 7.19 (t, 1H, J = 7.6 Hz), 7.10 (d, 1H, J = 7.6 Hz), 3.73 (s, 3H), 3.66 (s, 3H), 3.48-3.54 (m, 
1H), 3.40 (dd, 1H, J = 15.6, 6.0 Hz), 3.21 (dd, 1H, 15.6, 8.0 Hz), 2.87 (dd, 1H, J = 16.8, 8.0 Hz), 2.71 (dd, 1H, J = 
16.8, 5.6 Hz), 2.58 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 173.5 171.9, 163.1, 150.7, 140.5, 130.4, 125.0, 124.6, 
107.8, 52.5, 52.0, 39.2, 35.0, 30.3, 16.6; IR (ATR) 3027, 2998, 2953, 2850, 1735 cm-1; LRMS (ESI + APCI) m/z 
[C15H18NO5]+ ([M+H]+) calcd 292.1, found 292.1. 
4cj. Flash column chromatography on silica gel (2 x 5% ! 10% EtOAc in Hex) 
yielded a very light brown oil (76%). Rf = 0.26 (10% EtOAc in Hex); HPLC analysis – 
Chiracel IC column, 98:2 Hex:iPrOH, 1.0 mL/min, major enantiomer: 8.3 min, minor 
enantiomer: 7.5 min, 96% ee; [α]D25 = -2.1° (c = 3.590 g/100 mL, CDCl3);[11] 1H NMR 
(400 MHz, CDCl3) δ 7.28 (d, 1H, J = 8.0 Hz), 7.17 (m, 1H), 7.08 (d, 1H, J = 7.6 Hz), 4.10-4.21 (m, 2H), 3.56-3.65 
(m, 2H), 3.26-3.33 (m, 1H), 3.04-3.11 (m, 2H), 2.57 (s, 3H), 1.49-1.84 (m, 4H), 1.21 (t, 3H, J = 7.2 Hz), 0.85 (s, 9H), 
0.02 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 174.5, 164.2, 150.7, 140.6, 130.2, 124.8, 124.4, 107.8, 62.7, 60.8, 43.2, 
31.1, 30.2, 28.6, 26.0, 18.4, 16.6, 14.3, -5.2; IR (ATR) 2953, 2928, 2856, 1733, 1610 cm-1; LRMS (ESI + APCI) m/z 
[C22H36NO4Si]+ ([M+H]+) calcd 406.2, found 406.3. 
4aa. Flash column chromatography on silica gel (50:44:6 Hex:DCM:Et2O) yielded a 

















column, 80:20 Hex:iPrOH, 1.0 mL/min, major enantiomer: 6.8 min, minor enantiomer: 6.4 min, 87% ee; [α]D25 = 
+3.09° (c = 1.080 g/100 mL, CDCl3); 1H NMR (400 MHz, CDCl3) δ 7.65-7.69 (m, 1H), 7.45-7.50 (m, 1H), 7.28-7.32 
(m, 2H), 4.16 (q, 2H, J = 7.2 Hz), 3.35 (dd, 1H, J = 15.6, 7.2 Hz), 3.16 (m, 1H), 3.03 (dd, 1H, J = 15.6, 7.2 Hz), 1.32 
(d, 3H, J = 7.2 Hz), 1.22 (t, 3H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 175.0, 165.1, 150.9, 141.4, 124.8, 124.3, 
119.8, 110.5, 61.0, 37.7, 32.3, 17.3, 14.3; IR (ATR) 2979, 2928, 1731, 1615, 1572 cm-1; LRMS (ESI + APCI) m/z 
[C13H16NO3]+ ([M+H]+) calcd 234.1, found 234.1. 
4ea. Flash column chromatography on silica gel (DCM ! 2% ! 5% ! 10% Et2O in 
DCM) yielded a colorless oil (35%). Rf = 0.30 (8:1 Hex:Acetone); HPLC analysis – 
Chiracel IB column, 94:6 Hex:10% iPrOH in Hex, 1.0 mL/min, major enantiomer: 
9.1 min, minor enantiomer: 8.4 min, 90% ee; [α]D25 = +8.9° (c = 1.155 g/100 mL, CDCl3); 1H NMR (400 MHz, 
CDCl3) δ 7.65 (d, 1H, J = 2.0 Hz), 7.39 (d, 1H, J = 8.8 Hz), 7.27 (dd, 1H, J = 8.8, 2.0 Hz), 4.16 (q, 2H, J = 7.2 Hz), 
3.34 (dd, 1H, J = 15.6, 7.2 Hz), 3.10-3.10 (m, 1H), 3.03 (dd, 1H, J = 15.6, 7.2 Hz), 1.32 (d, 3H, J = 7.2 Hz), 1.22 (t, 
3H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 174.6, 166.4, 149.3, 142.4, 129.7, 124.9, 119.7, 111.0, 60.8, 37.4, 
32.1, 17.1, 14.1; IR (ATR) 3096, 2980, 2938, 1732, 1568, 1451 cm-1; LRMS (ESI + APCI) m/z [C13H15ClNO3]+ 
([M+H]+) calcd 268.1, found 268.0. 
4fa. The crude reaction mixture was dried under high vacuum overnight to remove 
residual benzoxazole 1f, since it coelutes with 4fa. Flash column chromatography on 
silica gel (5:2 Hex:Et2O) yielded a light yellow oil (31%). Rf = 0.26 (5:2 Hex:Et2O); 
HPLC analysis – Chiracel IC column, 94:6 Hex:10% iPrOH in Hex, 1.0 mL/min, major enantiomer: 9.1 min, minor 
enantiomer: 8.4 min, 90% ee; [α]D25 = +3.0° (c = 0.970 g/100 mL, CDCl3); 1H NMR (400 MHz, CDCl3) δ 7.58 (dd, 
1H, J = 8.8, 4.8 Hz), 7.20 (dd, 1H, J = 8.0, 2.8 Hz), 7.04 (ddd, 1H, J = 9.2, 8.8, 2.8 Hz), 4.15 (q, 2H, J = 7.2 Hz), 3.32 
(dd, 1H, J = 15.6, 7.2 Hz), 3.13 (m, 1H), 3.00 (dd, 1H, J = 15.6, 6.8 Hz), 1.31 (d, 3H, J = 6.8 Hz), 1.22 (t, 3H); 13C 
NMR (100 MHz, CDCl3) δ 174.8, 165.6 (d, J = 3.1 Hz), 160.5 (d, J = 242 Hz), 150.8 (d, J = 14.6 Hz), 137.7, 120.0 
(d, J = 9.9 Hz), 112.2 (d, J = 24.4), 98.6 (d, J = 28.1 Hz), 61.0, 37.6, 32.3, 17.3, 14.3; 19F NMR (376 MHz, CDCl3) δ 
-116.1 (ddd, J = 9.2, 8.8, 4.8 Hz); IR (ATR) 3081, 2980, 2939, 2909, 1730, 1623 cm-1; LRMS (ESI + APCI) m/z 












4ga. Flash column chromatography on silica gel (DCM ! 1% ! 2% ! 4% ! 
10% ! 30% EtOAc in DCM) yielded a light golden oil (48%). Rf = 0.24 (4% 
EtOAc in DCM); HPLC analysis – Chiracel IC column, 90:10 Hex:iPrOH, 1.0 
mL/min, major enantiomer: 14.7 min, minor enantiomer: 13.5 min, 88% ee; [α]D25 = +3.1° (c = 1.580 g/100 mL, 
CDCl3); 1H NMR (400 MHz, CDCl3) δ 7.52 (d, 1H, J = 8.8 Hz), 7.00 (d, 1H, J = 2.4 Hz), 6.89 (dd, 1H, J = 8.8, 2.4 
Hz), 4.15 (q, 2H, J = 7.2 Hz), 3.84 (s, 3H), 3.30 (dd, 1H, J = 15.2, 6.8 Hz), 3.12 (m, 1H), 2.98 (dd, 1H, J = 15.2, 7.2 
Hz), 1.30 (d, 3H, J = 7.2 Hz), 1.22 (t, 3H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 175.0, 164.0, 158.0, 151.7, 
135.1, 119.7, 112.3, 95.5, 60.9, 56.1, 37.7, 32.3, 17.2, 14.3; IR (ATR) 2978, 2939, 2907, 2836, 1729, 1615 cm-1; 
LRMS (ESI + APCI) m/z [C14H18NO4]+ ([M+H]+) calcd 264.1, found 264.1. 
4ha. Flash column chromatography on silica gel (1% ! 2% ! 4% ! 10% ! 
30% EtOAc in DCM) yielded a colorless oil (56%). Rf = 0.15 (2% EtOAc in 
DCM); HPLC analysis – Chiracel IB column, 93:7 Hex:10% iPrOH in Hex, 1.0 
mL/min, major enantiomer: 17.1 min, minor enantiomer: 15.8 min, 77% ee; [α]D25 = +7.4° (c = 1.830 g/100 mL, 
CDCl3); 1H NMR (400 MHz, CDCl3) δ 7.34 (d, 1H, J = 9.2 Hz), 7.16 (d, 1H, J = 2.4 Hz), 6.89 (dd, 1H, J = 9.2, 2.4 
Hz), 4.15 (q, 2H, J = 7.2 Hz), 3.84 (s, 3H), 3.31 (dd, 1H, J = 15.6, 7.2 Hz), 3.13 (m, 1H), 2.99 (dd, J =15.6, 7.6 Hz), 
1.31 (d, 3H, J = 6.8 Hz), 1.22 (t, 3H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 174.9, 165.9, 157.2, 145.5, 142.2, 
113.2, 110.6, 103.0, 60.9, 56.1, 37.7, 32.4, 17.2, 14.3; IR (ATR) 2979, 2938, 2907, 2835, 1730, 1571 cm-1; LRMS 
(ESI + APCI) m/z [C14H18NO4]+ ([M+H]+) calcd 264.1, found 264.1. 
A.2.17 Mechanistic experiments 
A.2.17.1 Synthesis of 1c-D 
1c-D. In the glove box, a 1.5 dram vial was charged with [Rh(cod)OAc]2 (27.5 mg, 0.05 mmol, 2 
mol %) and dppe (40.5 mg, 0.10 mmol, 4 mol %). To this was added a solution of 1c (339 mg, 
300 µL, 2.55 mmol, 1.0 equiv) in PhMe (2000 µL). MeOH-d4 (910 µL) was added, and the vial 
was sealed with a Teflon-lined stir cap. The reaction was removed from the glove box and heated to 120 °C in an 
aluminum heating block for 24 h. At this point, the crude reaction mixture was adsorbed onto silica gel and purified 
by flash column chromatography (7:1 Hex:EtOAc). The obtained product 1c-H/D was subjected to the same reaction, 

















Figure A.2.6 1H NMR spectrum of 1c-D (top) and 1c (bottom) in CDCl3 
 
A.2.17.2 Reaction of 1c-D and 3a in CH3CN (Chapter 2, Figure 2.7, eq. 12) 
Reaction set-up: In the glove box, a 1.5 dram vial containing [Rh(cod)OAc]2 (6.8 mg, 12.6 µmol, 5 mol %) and 
CTH-(R)-xylyl-P-Phos (18.9 mg, 25.2 µmol, 10 mol %) was charged with a solution of 1c-D (32.6 mg, 0.25 mmol, 
1.0 equiv) and DTBB (6.6 mg, 25.0 µmol, 0.10 equiv) in 500 µL CH3CN. Ethyl methacrylate (3a) (228 mg, 250 µL, 
2.0 mmol, 8.0 equiv) was added, and the vial was sealed with a Teflon-lined stir cap. The reaction was removed from 
the glove box and heated to 100 °C in an aluminum block for 12 h.  
Percent yield and percent ee determination: Percent yield and percent ee of 4ca was determined by LC 
analysis of the crude reaction mixture on a chiral stationary phase as described above for initial reaction optimization 
(A.2.12.2). 4ca: 42%, 96% ee 
Determination of percent 1H incorporation in 1c: Percent 1H incorporation in 1c was determined by 1H NMR 
analysis of the crude reaction mixture (Figure A.2.7).  
 
Figure A.2.7 Percent 1H incorporation in 1c determined by 1H NMR analysis of crude reaction mixture (Chapter 2, 






Determination of percent deuterium incorporation in 4ca: Percent 2H incorporation in product 4ca was 
determined by 1H NMR analysis of pure 4ca obtained by flash column chromatography on silica gel (2 x 7:1 
Hex:EtOAc) (Figure A.2.8). 
Figure A.2.8 Percent 2H incorporation in 4ca determined by 1H NMR analysis of pure 4ca (Chapter 2, Figure 2.7, eq. 
12)  
A.2.17.3 Reaction of 1c-D and 3a in CD3CN (Chapter 2, Figure 2.7, eq. 13) 
Reaction set-up: In the glove box, a 1.5 dram vial containing [Rh(cod)OAc]2 (6.8 mg, 12.6 µmol, 5 mol %) and 
CTH-(R)-xylyl-P-Phos (18.9 mg, 25.2 µmol, 10 mol %) was charged with a solution of 1c-D (32.6 mg, 0.25 mmol, 
1.0 equiv) and DTBB (6.6 mg, 25.0 µmol, 0.10 equiv) in 500 µL CD3CN. Ethyl methacrylate (3a) (228 mg, 250 µL, 
2.0 mmol, 8.0 equiv) was added, and the vial was sealed with a Teflon-lined stir cap. The reaction was removed from 
the glove box and heated to 100 °C in an aluminum block for 12 h.  
Percent yield and percent ee determination: Percent yield and percent ee of 4ca was determined by LC 
analysis of the crude reaction mixture on a chiral stationary phase as described above for initial reaction optimization 
(A.2.12.2). 4ca: 47%, 96% ee 
Determination of percent 1H incorporation in 1c: Percent 1H incorporation in 1c was determined by 1H NMR 















Figure A.2.9 Percent 1H incorporation in 1c determined by 1H NMR analysis of crude reaction mixture (Chapter 2, 
Figure 2.7, eq. 13) 
Determination of percent deuterium incorporation in 4ca: Percent 2H incorporation in product 4ca was 
determined by 1H NMR analysis of pure 4ca obtained by flash column chromatography on silica gel (2 x 7:1 
Hex:EtOAc) (Figure A.2.10). 
 
Figure A.2.10 Percent 2H incorporation in 4ca determined by 1H NMR analysis of pure 4ca (Chapter 2, Figure 2.7, 
eq. 13)  
A.2.17.4 Reaction of 1c and 3b-d8 in CH3CN (Chapter 2, Figure 2.7, eq. 14) 
Reaction set-up: In the glove box, a 1.5 dram vial containing [Rh(cod)OAc]2 (6.8 mg, 12.6 µmol, 5 mol %) and 
CTH-(R)-xylyl-P-Phos (18.9 mg, 25.2 µmol, 10 mol %) was charged with a solution of 1c (32.0 mg, 0.25 mmol, 1.0 
equiv) and DTBB (6.6 mg, 25.0 µmol, 0.10 equiv) in 500 µL CH3CN. Ethyl methacrylate (3b-d8) (216 mg, 214 µL, 
2.0 mmol, 8.0 equiv) was added, and the vial was sealed with a Teflon-lined stir cap. The reaction was removed from 















Percent yield and percent ee determination: Percent ee of 4cb was determined by LC analysis on a chiral 
stationary phase as described above for initial reaction optimization (A.2.12.2). Percent yield of 4cb was determined 
with respect to DTBB by 1H NMR analysis of the crude reaction mixture.  
Determination of percent 1H incorporation in 4ca: Percent 1H incorporation in product 4cb was determined by 
1H NMR analysis of pure 4cb obtained by flash column chromatography on silica gel (7:1 Hex:EtOAc) (Figure 
A.2.11). 
Note: The total percent 1H incorporation in 4cb exceeds the one hundred percent that would be expected were 1c 
the only 1H source. We account for greater than one hundred percent 1H incorporation by invoking reversible C–H 
activation at the β-position of product 4cb and protonation with CH3CN (vide infra, section A.2.17.6).  
Figure A.2.11 Percent 1H incorporation in 4cb determined by 1H NMR analysis of pure 4cb (Chapter 2, Figure 2.7, 
eq. 14)  
A.2.17.5 Epimerization experiments (Chapter 2, Figure 2.9, eq. 15–17) 
A.2.17.5.1 General procedure  
In the glove box, a 1.5 dram vial containing [Rh(cod)OAc]2 (3.4 mg, 6.3 µmol, 5 mol %), CTH-(R)-xylyl-P-Phos 
(9.5 mg, 12.6 µmol, 10 mol %) was charged with a solution of 1c (16.6 mg, 15.0 µL, 0.125 mmol, 1.0 equiv), DTBB 
(3.3 mg, 12.5 µmol, 0.10 equiv) and 4 (0.063 mmol, 0.5 equiv) in 250 µL CH3CN. The appropriate acrylate 3 (1.0 
mmol, 8.0 equiv) was added, and the vial was sealed with a Teflon-lined stir cap. The reaction was removed from the 
glove box and heated to 100 °C in an aluminum block for 48 h. Percent yield and percent ee of products 4 were 












A.2.17.5.2 A note on HPLC retention times 
Slight variation in retention time across products 4 is sometimes observed. We attribute this at least in part to the 
very low polarity of typical column conditions. We use a premade solution of 10 % iPrOH in Hex as the polar 
component. The concentration of this mixture can vary from batch to batch. Moreover, polar solvents such as CD3CN 
or CDCl3 introduced from the crude reaction or from NMR samples can discernably modify retention times. 
A.2.17.5.3 A note on HPLC analysis of racemic mixures (see also section A.2.19) 
We make racemic CTH-xylyl-P-Phos (rac-L11) in situ by mixing small ( < 10 mg) quantities of (R)- and (S)-
L11. Racemic samples prepared in this way can have ees up to three percent. In general, the major enantiomer 
prepared from in situ rac-L11 is the same as that when (R) catalyst is used. This pattern may simply be random, or it 
could arise from differences in purity or physical properties between catalysts (while the R-catalyst is a fine, free-
flowing white power that is easily weighed, the S catalyst is a clumpy yellow solid that is difficult to weigh). 
A.2.17.5.4 Reaction of 1c, 3a and 4ha (77% ee) (Chapter 2, Figure 2.9, eq. 15) 
DTBB, 1c, 3a, both enantiomers of 4ha and both enantiomers of 4ca are all separable on Chiracel IB column, 
94:6 Hex:10% iPrOH in Hex, 1 mL/min: 
 DTBB: 3.4 min 
 Ethyl methacrylate (3a): 3.9 min (3a has a very low absorbance) 
 4-methylbenzoxazole (1c): 6.2 min 
 First enantiomer 4ca: 7.6 min (minor) 
 Second enantiomer 4ca: 8.5 min (major) 
 First enantiomer 4ha: 17.5 min (minor) 
 Second enantiomer 4ha: 19.0 min (major) 
Percent ee of 4ca and 4ha were determined by HPLC analysis (see HPLC data on next page, Figure A.2.12). 
Percent yield 4ca was determined by HPLC analysis with respect to DTBB as described in initial reaction 
optimization (A.2.12.2). 
Percent yield 4ha was determined with respect to DTBB by 1H NMR. 
Results: 
 w/o CsOAc—4ca: 70%, 95% ee; 4ha: > 95%, 50% ee 
 w/ 25 mol % CsOAc—4ca: 81%, 95% ee; 4ha: > 95%, 50% ee 
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Figure A.2.12 HPLC data from epimierization study of 4ha in presence of 1c and 3a  (Chapter 2, Figure 2.9, eq. 15). 































A.2.17.5.5 Reaction of 1c, 3a and 4ga (88% ee) (Chapter 2, Figure 2.9, eq. 16) 
Percent yield and percent ee 4ca were determined as for the reaction of 1c, 3a and 4ha above (A.2.17.5.4 and 
A.2.12.2). Note: Both enantiomers of 4ga elute after 20 min using Chiracel IB column, 94:6 Hex:10% iPrOH in Hex, 
1 mL/min. 
For ee analysis of 4ca, see Figure A.2.13 below. 
Percent ee 4ga was determined by HPLC analysis: Chiracel IC column, 90:10 Hex:iPrOH, 1 mL/min: 
 First enantiomer 4ga: 13.8 min (minor) 
 Second enantiomer 4ga: 14.8 min (major) 
 DTBB, 1c, 3a and 4ca elute before 7.5 min. 
For ee analysis of 4ga, see Figure A.2.14 on next page. 
Percent yield 4ga was determined with respect to DTBB by 1H NMR. 
Results: 4ca: > 95%, 95% ee; 4ga: > 95%, 74% ee 
 
Figure A.2.13 HPLC data from epimierization study of 4ga in the presence of 1c and 3a (Chapter 2, Figure 2.9, eq. 
16). Crude reaction mixture under conditions that separate enantiomers of 4ca. Note: Both enantiomers of 4ga elute 










Figure A.2.14 HPLC data from epimerization study of 4ga in the presence of 1c and 3a (Chapter 2, Figure 2.9, eq. 
16). Top: pure 4ga (88% ee); Middle: racemic 4ca; Bottom: crude reaction mixture. Note: ee data for 4ca was 






















A.2.17.5.6 Reaction of 1c, 3c and 4ca (95% ee) (Chapter 2, Figure 2.9, eq. 17) 
Relevant species are all separable under column conditions used for initial reaction optimization (A.2.12.2): 
 DTBB: 3.4 min 
 3c: 4.8 min  
 4-methylbenzoxazole (1c): 6.2 min 
 First enantiomer 4ca: 7.6 min (minor) 
 Second enantiomer 4ca: 8.5 min (major) 
 First enantiomer 4cc: 13.6 min (minor) 
 Second enantiomer 4cc: 19.1 min (major) 
Percent yield and percent ee 4ca were determined as for the reaction of 1c, 3a and 4ha above (A.2.17.5.4 and 
A.2.12.2) (see Figure A.2.15 on next page). 
Percent ee 4cc was determined by HPLC analysis (see Figure A.2.15 on next page), and percent yield 4cc was 
determined with respect to DTBB by 1H NMR. 
Results: 4cc: > 95%, 90% ee; 4ca: > 95%, 93% ee 
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Figure A.2.15 HPLC data from epimierization study of 4ca in the presence of 1c and 3c (Chapter 2, Figure 2.9, eq. 






























A.2.17.6 Epimerization–labeling experiments of 4ha and 4ca in CD3CN (Chapter 2, Figure 2.11, eq. 18–19) 
In the glove box, a 1.5 dram vial containing [Rh(cod)OAc]2 (3.4 mg, 6.3 µmol, 13 mol %), CTH-(R)-xylyl-P-
Phos (9.5 mg, 12.6 µmol, 26 mol %) was charged with a solution of 4ha (75% ee) or 4ca (95% ee) (0.05 mmol, 1.0 
equiv) in 105 µL CD3CN. The vial was sealed with a Teflon-lined screw cap, removed from the glove box and heated 
to 100 °C in an aluminum block for 48 h. The crude reaction mixture was adsorbed onto silica gel and purified by 
flash column chromatography—4ha: 3:1 Hex:EtOAc and 4ca: 7:1 Hex:EtOAc. Percent 2H incorporation was 
determined by 1H NMR analysis of the pure products (Figure A.2.16–A.2.17). Percent ee 4ha and 4ca determined by 
LC analysis of crude or purified reaction (Figure A.2.18–A.2.19, next page). 
 
Figure A.2.16 1H NMR spectrum of pure 4ha in CDCl3 (Chapter 2, Figure 2.11, eq. 18) 
 
















Figure A.2.18 HPLC data from epimerization reaction of 4ha in CD3CN (Chapter 2, Figure 2.11, eq. 18). Top: 4ha 


















Figure A.2.19 HPLC data from epimerization reaction of 4ca in CD3CN (Chapter 2, Figure 2.11, eq. 19). Top: 4ca 






















































































































































































































































































































































































Table 1.  Crystal data and structure refinement for [Rh(cod)OAc]2 
Identification code  rovis139_0m 
Empirical formula  C20H30O4Rh2 
Formula weight  540.26 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.9223(8) Å α= 103.826(4)°. 
 b = 9.9063(8) Å β= 90.574(5)°. 
 c = 12.6748(11) Å γ = 112.147(4)°. 
Volume 1001.31(15) Å3 
Z 2 
Density (calculated) 1.792 Mg/m3 
Absorption coefficient 1.670 mm-1 
F(000) 544 
Crystal size 0.21 x 0.14 x 0.10 mm3 
Theta range for data collection 1.66 to 33.41°. 
Index ranges -13<=h<=13, -15<=k<=15, -19<=l<=19 
Reflections collected 27291 
Independent reflections 7666 [R(int) = 0.0256] 
Completeness to theta = 33.41° 98.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8495 and 0.7248 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7666 / 0 / 237 
Goodness-of-fit on F2 1.088 
Final R indices [I>2sigma(I)] R1 = 0.0324, wR2 = 0.0722 
R indices (all data) R1 = 0.0604, wR2 = 0.0909 
Largest diff. peak and hole 0.831 and -0.492 e.Å-3 
 137 
Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for Rovis139_0m.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 11185(3) 3719(3) 996(2) 43(1) 
C(2) 11027(4) 2227(3) 620(2) 44(1) 
C(3) 12303(4) 1664(3) 901(3) 56(1) 
C(4) 11961(4) 1056(4) 1908(3) 55(1) 
C(5) 11088(3) 1809(3) 2684(2) 43(1) 
C(6) 11523(3) 3366(3) 3063(2) 40(1) 
C(7) 13027(4) 4514(3) 2762(3) 52(1) 
C(8) 12633(4) 4949(3) 1736(3) 52(1) 
C(9) 6809(3) 2434(3) 326(2) 33(1) 
C(10) 5711(3) 1618(3) -737(2) 43(1) 
C(11) 6606(3) 1843(3) 3161(2) 32(1) 
C(12) 5456(3) 824(3) 3773(2) 48(1) 
C(13) 9422(4) 6740(3) 2170(2) 41(1) 
C(14) 10686(4) 7718(3) 3145(2) 48(1) 
C(15) 10581(4) 6895(3) 4048(2) 47(1) 
C(16) 8887(4) 5745(3) 4038(2) 41(1) 
C(17) 7478(4) 6039(3) 4031(2) 44(1) 
C(18) 7485(4) 7585(4) 4051(3) 58(1) 
C(19) 7226(4) 7723(3) 2891(3) 52(1) 
C(20) 7881(4) 6784(3) 2061(2) 43(1) 
O(1) 7876(2) 1635(2) 2960(2) 45(1) 
O(2) 6221(2) 2832(2) 2924(2) 44(1) 
O(3) 7602(2) 1773(2) 635(2) 46(1) 
O(4) 6848(3) 3703(2) 817(2) 46(1) 
Rh(1) 7636(1) 4800(1) 2475(1) 31(1) 







Table 3.   Bond lengths [Å] and angles [°] for  Rovis139_0m. 
_____________________________________________________  
C(1)-C(2)  1.392(4) 
C(1)-C(8)  1.509(4) 
C(1)-Rh(2)  2.085(2) 
C(2)-C(3)  1.517(4) 
C(2)-Rh(2)  2.096(3) 
C(3)-C(4)  1.524(4) 
C(4)-C(5)  1.494(4) 
C(5)-C(6)  1.398(4) 
C(5)-Rh(2)  2.080(3) 
C(6)-C(7)  1.518(4) 
C(6)-Rh(2)  2.106(3) 
C(7)-C(8)  1.540(4) 
C(9)-O(3)  1.244(3) 
C(9)-O(4)  1.249(3) 
C(9)-C(10)  1.511(3) 
C(11)-O(1)  1.245(3) 
C(11)-O(2)  1.249(3) 
C(11)-C(12)  1.511(3) 
C(13)-C(20)  1.398(4) 
C(13)-C(14)  1.521(4) 
C(13)-Rh(1)  2.107(3) 
C(14)-C(15)  1.540(4) 
C(15)-C(16)  1.510(4) 
C(16)-C(17)  1.393(4) 
C(16)-Rh(1)  2.081(3) 
C(17)-C(18)  1.524(4) 
C(17)-Rh(1)  2.097(3) 
C(18)-C(19)  1.532(4) 
C(19)-C(20)  1.506(4) 
C(20)-Rh(1)  2.087(2) 
O(1)-Rh(2)  2.0954(17) 
O(2)-Rh(1)  2.0999(17) 
O(3)-Rh(2)  2.0894(18) 














































































Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters  (Å2x 103) for Rovis139_0m.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 43(2)  48(2) 38(2)  18(1) 14(1)  14(1) 
C(2) 42(2)  49(2) 32(1)  8(1) 12(1)  11(1) 
C(3) 40(2)  48(2) 70(2)  -4(2) 19(2)  17(1) 
C(4) 43(2)  51(2) 73(2)  11(2) -5(2)  25(2) 
C(5) 39(2)  50(2) 46(2)  20(1) 0(1)  21(1) 
C(6) 36(2)  52(2) 32(1)  7(1) -1(1)  21(1) 
C(7) 34(2)  46(2) 62(2)  -5(2) -3(1)  11(1) 
C(8) 43(2)  41(2) 65(2)  12(2) 20(2)  8(1) 
C(9) 29(1)  35(1) 31(1)  11(1) 5(1)  9(1) 
C(10) 44(2)  47(2) 32(1)  5(1) -4(1)  15(1) 
C(11) 27(1)  32(1) 35(1)  9(1) 5(1)  9(1) 
C(12) 41(2)  54(2) 54(2)  29(2) 18(1)  15(1) 
C(13) 51(2)  35(1) 40(2)  16(1) 9(1)  16(1) 
C(14) 43(2)  38(1) 53(2)  6(1) 0(1)  9(1) 
C(15) 45(2)  47(2) 42(2)  5(1) -7(1)  15(1) 
C(16) 50(2)  46(2) 27(1)  9(1) 0(1)  19(1) 
C(17) 51(2)  53(2) 31(1)  7(1) 9(1)  26(1) 
C(18) 62(2)  54(2) 57(2)  -3(2) 9(2)  33(2) 
C(19) 54(2)  36(1) 70(2)  9(1) -3(2)  23(1) 
C(20) 54(2)  34(1) 42(2)  15(1) -5(1)  15(1) 
O(1) 37(1)  54(1) 59(1)  32(1) 21(1)  22(1) 
O(2) 35(1)  42(1) 62(1)  24(1) 10(1)  16(1) 
O(3) 43(1)  43(1) 48(1)  -1(1) -12(1)  20(1) 
O(4) 64(1)  38(1) 35(1)  3(1) -11(1)  21(1) 
Rh(1) 36(1)  28(1) 29(1)  7(1) 0(1)  13(1) 
Rh(2) 24(1)  35(1) 31(1)  10(1) 4(1)  11(1) 
______________________________________________________________________________ 
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Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for Rovis139_0m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 10685 4075 466 51 
H(2) 10429 1707 -129 53 
H(3A) 13390 2502 1037 67 
H(3B) 12318 855 272 67 
H(4A) 11296 -43 1673 66 
H(4B) 13005 1204 2292 66 
H(5) 10568 1237 3225 51 
H(6) 11254 3699 3820 48 
H(7A) 13868 4087 2626 63 
H(7B) 13473 5431 3381 63 
H(8A) 12413 5878 1964 62 
H(8B) 13595 5174 1323 62 
H(10A) 6363 1419 -1326 64 
H(10B) 5165 2247 -905 64 
H(10C) 4893 660 -668 64 
H(12A) 5226 -233 3399 72 
H(12B) 4437 985 3796 72 
H(12C) 5958 1057 4520 72 
H(13) 9889 6546 1463 49 
H(14A) 10518 8662 3446 57 
H(14B) 11788 7993 2900 57 
H(15A) 11351 6382 3945 56 
H(15B) 10913 7647 4769 56 
H(16) 8846 4983 4444 49 
H(17) 6616 5448 4431 53 
H(18A) 8538 8380 4421 69 
H(18B) 6610 7743 4473 69 
H(19A) 6046 7400 2682 63 
H(19B) 7770 8795 2883 63 
H(20) 7454 6617 1288 52 
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Figure A.2.20 X-ray crystal structure of [Rh(cod)OAc]2 (obtained by Dr. Kevin Martin Oberg) 
